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ABSTRACT
BROOKS ALBERT SWANSON. Antibiotic Disruption of Oral Microbiota Dysregulates the
Osteoimmune Response and Alveolar Bone Homeostasis in the Healthy Periodontium.
(Under the direction of CHAD NOVINCE).
Problem: A balanced relationship between the host and oral microbiota supports
periodontal health and alveolar bone homeostasis. Antibiotic perturbation of the gut
microbiota critically regulates the osteoimmune response at non-oral skeletal sites.
However, the impact of antibiotics on the oral microbiota and osteoimmune mechanisms
regulating alveolar bone homeostasis are unknown. Considering that periodontitis driven
bone loss is caused by dysbiotic shifts in the oral microbiome, antibiotic disruption of the
oral microbiota may have deleterious effects on alveolar bone homeostasis.
Approach: Drinking water of sex-matched C57BL/6T specific-pathogen-free (SPF) mice
was supplemented with minocycline (MINO) or vehicle (VEH) control treatment from age
6 to 12 weeks. SPF mice were euthanized at age 12 weeks to assess immediate effects
and at age 18 weeks to evaluate sustained minocycline effects. 16S rDNA analysis was
performed to evaluate bacterial load and phylum level alterations in the oral microbiome.
Micro-CT was utilized to assess linear alveolar bone loss in the maxilla and
cortical/trabecular bone microarchitecture in the mandible. qRT-PCR analysis was
carried out to assess pro-osteoclastic and pro-inflammatory genes in the mandible bone
marrow (MBM) and gingiva. TRAP+ osteoclastic cell outcomes in alveolar bone were
evaluated by in situ and in vitro approaches. Flow cytometric analysis of immune cells
was performed in MBM and cervical lymph nodes (CLNs). In a separate experiment,
drinking water of male C57BL/6T germ-free (GF) mice was supplemented with MINO or
VEH treatment from age 6 to 12 weeks.
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Results: MINO treatment increased overall bacterial load and induced phylum level
alterations in the oral bacteriome of 12-week-old male SPF mice. Disruption of phylum
level bacterial communities were sustained in 18-week-old male SPF mice. The effects
of MINO treatment on the oral microbiota were sex-dependent as no alterations were
seen in female mice. MINO treatment induced linear alveolar bone loss in both male and
female SPF mice at the age 12 weeks and these effects persisted at age 18 weeks.
Validating that MINO-induced catabolic effects on alveolar bone is dependent on the oral
microbiota, no differences were found in linear alveolar bone loss in MINO vs. VEH
treated male GF mice. Cortical bone thickness was decreased in the mandible in
response to MINO treatment. Osteoclast cell size and bone interface were increased in
maxillary alveolar bone sections from MINO vs. VEH treated male SPF mice. Exogenous
MINO stimulation in MBM cultures derived from naïve 12-week-old male SPF mice
increased osteoclast size and number of nuclei. Intriguingly, these findings suggest that
MINO-induced pro-osteoclastic effects could be in part independent of the microbiota.
Pro-inflammatory plasmacytoid dendritic cells (DCs) were upregulated within MBM and
CLNs of MINO vs. VEH treated male SPF mice. Paralleling the plasmacytoid DCs, MINO
treatment profoundly increased TH1 and TH17 cell populations in the MBM and CLNs.
Conclusion: The current investigation reveals that MINO disruption of oral microbiota
induces a pro-inflammatory immune response, which upregulates osteoclastogenesis,
and drives alveolar bone loss. This novel research shows that oral MINO therapy, a
commonly prescribed antibiotic treatment, may have detrimental clinical effects on
alveolar bone in the healthy periodontium.
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CHAPTER 1: INTRODUCTION
1.1 Problem Statement
The commensal oral microbiota is a critical regulator of health and disease in the
human body, having effects on food digestion, dental caries, oral cancer, and oral
infectious diseases, specifically periodontitis.1,2 Periodontal disease is a chronic
inflammatory disease of the periodontium and is the most common oral condition of the
human population.3 Important to this proposal, the homeostasis between the commensal
oral microbiota and host immune response regulates alveolar bone remodeling in the
healthy periodontium.4 Studies utilizing the specific pathogen free (SPF) vs. germfree
(GF) mouse model have discerned that the commensal oral microbiota enhances
osteoclastogenesis and has catabolic effects on alveolar bone homeostasis during
health.4-7 The commensal oral microbiota increases alveolar bone loss and enhances
osteoclast precursor cell potential to differentiate into osteoclastic cells lining alveolar
bone.4 Increased pro-inflammatory cytokines (IL17, IL6, IL-1β), which enhance
osteoclastogenesis, correlate with decreased alveolar bone height in SPF vs. GF
mice.5,7 Irie, Novince, and Darvaeu (2014) recently showed that the commensal oral
microbiota increased the frequency of TRAP+ osteoclastic cells and RANKL+ cells at the
alveolar bone surface, as well as significantly increased numbers of neutrophils, which
highlights that the oral microbiota drives pro-inflammatory immune response effects that
lead to alveolar bone loss.4 Recent human periodontitis studies demonstrating a link
between the disruption of the oral microbiota and host inflammatory response, have
shown an oral microbial imbalance induces alterations in gene expression lineage and
leads to increased local TH17 cells to promote periodontal disease.8 Periodontal mouse
model studies have shown that bone loss was decreased after administration of soluble
10

decoy receptors for IL-1α, IL-1β, or TNF9-11 and also in mice deficient in host
inflammatory mediators, such as IFNγ, IL-6, or TNF receptor 1.12,13
Antibiotics are well known to induce shifts and alterations in the microbial
composition within the gut, which have indirect effects on host immunity and
physiology.14-16 We have previously shown that the antibiotic disruption of gut microbiota
composition alters host immune response effects, which increased osteoclast activity
and impaired bone mass accrual at non-oral skeletal sites.17 However, the effects of an
antibiotic-disrupted commensal oral microbiota and its impact on the osteoimmune
response and alveolar bone homeostasis is currently unknown.

1.2 Hypothesis
Antibiotic perturbation of the oral microbiota regulates the osteoimmune response and
alveolar bone homeostasis.
1.3 Specific Aims
Aim 1: Evaluate the persistence of minocycline treatment effects on the oral microbiome
and alveolar bone homeostasis.
Aim 2: Investigate the impact of antibiotic treatment effects on skeletal homeostasis and
osteoimmune response mechanisms within the alveolar bone complex.
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1.4 Background and Significance
General background on the periodontium and alveolar bone complex

Figure 1: Structure of the Periodontium
Note: Figure was adapted from Hathaway1
Schrader and Novince (2020).

The major components of the periodontium are the gingiva, periodontal ligament,
cementum, and alveolar bone (Figure 1). The periodontium supports the teeth,
dynamically acting as a suspensory apparatus resilient to normal functional and
mastication forces.18 Continuously adapting to masticatory demands, each of the
periodontal tissues is unique in location, structure, and biochemical properties.18
The gingiva is the external barrier tissue of the periodontium, and functions to
offer immediate protection for the underlying alveolar bone (Figure 1). The gingiva
surrounds the tooth like a collar and is firmly bound to the alveolar bone and cervical
portion of the tooth.19 The dentogingival junction, which consists of the epithelial and
connective tissue attachment to the tooth, serves to protect to subjacent alveolar bone
12

from dental plaque biofilm resident microbes.20,21 While epithelial tissues at external
body surfaces act as an impermeable barrier to colonization of microbial biofilms, the
junctional epithelium (Figure 1) attachment at the tooth surface is known to be highly
permeable.20
The main function of the junctional epithelium is to form a unique seal between
the root surface and gingiva to provide protection against the constant exposure of oral
microbes and their byproducts.20 Salivary proteins accumulate on the tooth surface to
form the acquired pellicle.22 Primary colonizers have adhesins that bind to
complimentary salivary protein receptors in the acquired pellicle. Primary colonizers then
provide receptors for secondary colonizers.22 As a result of poor oral hygiene, the
accumulation of dental plaque occurs, which provides a reservoir for the increase in
periodontal pathogenic (perio-pathogenic) bacteria. Perio-pathogenic bacteria have
invasive / evasive abilities and synthesize proteases that break down the epithelial
physical barrier.22 If the periodontium is constantly subjected to challenge by periopathogenic bacteria, the periodontal immune defense mounts an exacerbated proinflammatory response.22
The cementum is a specialized mineralized surface layer of the tooth root and
attaches the teeth to the alveolar bone by anchoring the periodontal ligament (PDL)
(Figure 1).23 The PDL is a specialized connective tissue that attaches the teeth to
surrounding alveolar bone.24 Since teeth are not embedded into the alveolar bone
directly, the periodontal ligament uses sensory receptors to ameliorate the impact of
compressive forces generated during mastication on the alveolar bone.25 The PDL also
contains pluripotent stem cells that aid in regeneration and maintenance of the tissues
within the periodontium.26
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Continuous challenge by perio-pathogenic bacteria induces chronic inflammation
which dysregulates collagen tissue remodeling. Apical migration of the junctional
epithelium and periodontal pocket formation occurs due to degradation of collagen in the
periodontal ligament and gingival connective tissue.20 If poor hygiene persists, gram
negative perio-pathogenic bacteria will continue to drive a chronic pro-inflammatory
immune response state which leads to progressive tissue destruction and alveolar bone
loss.22
The cementoenamel junction (CEJ) represents the anatomic limit between the
enamel crown and cementum root surface, and is located at the cervical region of the
tooth (Figure 1).27 One of the most important parameters for assessing periodontal
destruction is evaluating the linear distance from the CEJ to alveolar bone crest (ABC).
In periodontal disease states, the crest of the alveolar bone migrates apically, moving
away from the CEJ and towards the root apex.27 Studies have reported that a normal
CEJ to ABC distance of 1 +/- 0.5 mm exists in the healthy primary dentition,28,29 and a
distance of 2 mm or greater is considered to represent alveolar bone loss.28 Periopathogenic bacteria drive alveolar bone loss through the induction of a chronic proinflammatory host immune response, that spreads deep into the gingival connective
tissue as an inflammatory cell infiltrate.30 This pro-inflammatory state dysregulates
fibroblast-mediated remodeling of the gingival connective tissue and the PDL, which
leads to reduced collagen content and compromised tissue integrity.31,32 As this process
continues, irreversible detachment of PDL collagen fibers occurs at the root surface,
which results in the junctional epithelium extending apically.31,32 As the subgingival
biofilms extend apically toward alveolar bone and the periodontal pocket deepens, proinflammatory immune response mediators stimulate osteoclast mediated alveolar bone
destruction.33,34
14

The formation of the alveolar bone is dependent on the development, eruption,
and maintenance of the teeth.35 The main function of the alveolar bone complex is to
protect the roots of the teeth and support masticatory function.35 The alveolar bone is
subjected to continual and rapid remodeling/turnover associated with tooth eruption and
the functional demands of mastication.36 Alveolar bone is a unique osseous tissue due to
its integration with the dentition and its close proximity to the resident oral microbiota
colonizing the teeth and gingival tissues.37 The alveolar bone complex is composed of
alveolar bone proper, supporting trabecular bone, and supporting cortical bone, which
consists of the lingual and buccal cortical plates (Figure 1).35 The mandible is primarily
composed of cortical bone, whereas the maxilla is primarily made up of trabecular
bone.38 The cortical bone is the thick outer layer of bone formed from compact bone on
the facial and lingual surfaces of the alveolar bone.36 The trabecular bone consists of
spongy cancellous bone that is found between the alveolar bone proper and the plates
of cortical bone.39 The alveolar bone is rich in marrow spaces, which serve as a reservoir
for hematopoietic and mesenchymal lineage cells.39 While the architecture and
morphology of the alveolar bone are unique to the functional demands of the
periodontium, cellular processes and activities within alveolar bone are similar to nonoral skeletal sites.36
General background on commensal oral microbiota / Host immune response in the oral
cavity
Early life host-microbe interactions regulate the development of the host immune
system and the formation of a diverse microbial community, which is referred to as the
commensal microbiota.40,41 The oral microbiota, the community of microbes colonizing
the oral cavity, play a critical role in regulating human health and disease.42 The oral
microbiota is the second most diverse microbial community colonizing the human body
15

with more than 1000 different bacterial species that colonize the hard surfaces of teeth
and the soft tissues of the oral mucosa.2,42-44 The predominant bacterial phyla
communities that make up the human oral microbiota include Proteobacteria,
Actinobacteria, Bacteroidetes, Firmicutes, Fusobacteria, and Spirochaetes.2
The oral microbiota has symbiotic effects that benefit the host, including the
development and refinement of the local and systemic immune system, and protection
against invading pathogenic microbes.42 The immune system consists of the innate and
adaptive immune responses. The innate immune response regulates the composition of
resident microbes within commensal microbiota communities, supporting a mutualistic
interaction where the host benefits directly from the microbiota’s metabolic activities.45 If
the immune cells dominating the innate response lose proper recognition of colonizing
bacteria, a dysbiosis between the host and microbiota can occur. Dysbiosis refers to the
disruption of symbiotic interactions between the host and microbiota and can often lead
to health consequences, such as inflammation or disease states.46 Periodontal disease
is a chronic inflammatory disease in the oral cavity that affects the periodontal tissues
and bone supporting the teeth.47 Periodontal disease is caused by a disruption of
homeostasis between the host and oral microbiota.47 Perio- pathogenic bacteria become
more prominent within the oral flora, which stimulates the expression of pro-inflammatory
cytokines that induce periodontal tissue destruction.47 According to recent finding,
approximately 47% of American adults have periodontal disease.48
The balanced relationship between the oral microbiota and host immune
response is dependent on the recognition of commensal microbiota derived microbialassociated molecular patterns (MAMPs) at pattern-recognition receptor (PRR)expressing host cells.49-51 PPRs play an important role in innate immunity by recognizing
MAMPs, which include microbial cell wall macromolecules, nucleic acids, and other
16

evolutionary conserved molecular motifs uniquely conserved by microorganisms.49-51
MAMPs signaling enables the host to distinguish between self and the colonizing
microbiota.49-51 MAMPs activate the PRR-expressing epithelial cells within the oral cavity
and function as specific molecular ligands with high affinity to PRRs.52 When bound to
PRR-expressing host cells, MAMPs induce signaling cascades, which lead to the
expression of pro-inflammatory cytokines (IL-1B, IL-6, TNF) and type 1 interferons (IFNa, IFN-B).49-51
The innate immune response constitutes a homeostatic system in which innate
immune cells are able to recognize invading microorganisms as non-self and prompt
immune responses to eliminate them.53 As a part of the innate immune response of the
oral cavity, saliva and the gingival crevicular fluid serve as a liquid barrier by flushing
microbes and provide antimicrobial activity to maintain a symbiotic environment.54
Important to the innate immune response, the periodontal epithelial barrier excludes
environmental pathogens, exogenous substances, and resists mechanical stress.54 Loss
of integrity of the periodontal epithelium leads to the recruitment of pro-inflammatory
immune cells within the underlying gingival connective tissue. As the pro-inflammatory
cellular infiltrate spreads, apically towards the alveolar bone, pro-inflammatory cytokines
upregulate osteoclast mediated bone resorption.54
Neutrophils are the most abundant leukocytes in blood and the first responders in
the host immune defense.55 Neutrophils use adhesion molecules to attach to endothelial
cells within the blood vessels of the gingival connective tissue.55 Neutrophils exit the
gingiva blood vessels and travel through the gingival junctional epithelium until they
reach the gingival crevice. At the gingival crevice, neutrophils accumulate and create a
barrier wall to prevent the bacterial biofilm from growing and invading the underlying
tissues.55 While the lack of neutrophils has been proven to lead to periodontal
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breakdown, the excess of neutrophils has also been reported to lead to periodontal
tissue destruction.55 This innate immune cell population has generated a continued
interest in periodontitis due to its close proximity to the oral microbiota and its modulation
of other immune cells in periodontal health and disease.55
The influx of neutrophils in the innate immune response is closely followed by
monocytes that can differentiate into macrophages. In the inflamed periodontium,
monocytes are released from the bloodstream in gingival capillaries and produce
inflammatory cytokines, such as IL-1 and TNF.54 Monocyte-derived macrophage cells
engulf particular antigens, microbes, and apoptotic cells in the oral cavity.54
Macrophages can differentiate into two subpopulations: M1 and M2 macrophages. M1
and M2 macrophages have antigen presenting processes specific to effector CD4+ Tcells, thus providing a link between the innate and adaptive immune responses.54 M1
macrophage cells have been shown to be activated by IFNG and LPS,54 and produce
high levels of pro-inflammatory cytokines such as TNF, IL1B, and IL6.56 M2
macrophages have the ability to respond to IL4 and IL-3,54 and express high levels of
anti-inflammatory cytokine such IL10.56 M1 macrophages in the periodontium are proinflammatory in nature, and mediate the elimination of invading bacteria.56 M2
macrophages are anti-inflammatory in nature, and play a dominant role in periodontal
tissue repair and homeostasis.56
Dendritic cells (DCs) are innate immune cells that capture, process, and present
antigens to lymphocytes, which initiates and prompts the adaptive immune response.57
DCs are derived from the bone marrow and can be divided in to two subpopulations:
plasmacytoid DCs and conventional DCs.57 Plasmacytoid DCs are derived from
lymphoid progenitors and terminally differentiate in the bone marrow.57 Plasmacytoid
DCs mostly recognize viral antigens and specialize in the production and secretion of
18

type 1 interferons and pro-inflammatory chemokines.57 This subpopulation of DCs enters
the lymphoid nodes directly through the bloodstream and can act as antigen presenting
cells, but less efficiently than conventional DCs.57 Conventional DCs patrol various
tissues in the periodontium to recognize foreign antigens.57 Upon maturation,
conventional DCs migrate to the lymph nodes draining the oral cavity to present
microbial peptides to activate T-cells.57 DCs can potentially enhance periodontal disease
and the progression of alveolar bone loss through the upregulation of the TH1 and TH17
response.57
Table 1: Helper CD4+ T-Cell subsets, transcription factors, and cytokines
CD4+ T-cell subset

Transcription factor

Characteristic cytokine

T H1

T-BET

IFNG

TH17

RORγt

IL17A

TH22

AHR

IL22

TREG

FOXP3

IL10, TGFβ

Adaptive immune cells are the second line of defense and respond slower to
MAMPs than innate immune cells. Adaptive immunity differs from innate immunity in that
is it highly specific to antigens and has immunological memory, a concept providing
rapid and specific responses to reinfection.58 Adaptive immune cells are derived from
pluripotent hematopoietic stem cells in the bone marrow, and can differentiate into Tcells or B-cells.58,59 T-cell differentiation and maturation occurs within the thymus and is
characterized by ordered expression of various CD surface molecules.60 B-cell
maturation occurs in the bone marrow.58
In periodontal health and disease, CD4+ helper T-cells protect the host against
microbial invasion and regulate alveolar bone homeostasis.61 Demonstrating the
contribution of helper T-cells to periodontal tissue destruction, mice lacking CD4+ T-cells
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are resistant to bacteria induced alveolar bone loss.12 Important to the current study,
CD4+ helper T-cell subsets are defined by the expression of transcription factors and
secretion of specific cytokines (Table 1). CD4+ helper T-cell subsets examined in this
study have been characterized to play the following roles: TH1 cells generate cell
mediated immunity, TH17 cells maintain mucosal barrier function and have proinflammatory activity beneficial to the host during infection, TH22 cells defend against
tissue inflammation, and TREG cells regulate pro-inflammatory cytokine production and
overall immune homeostasis.62
In periodontitis, TH1 cells enhance the apoptotic activity of macrophages to engulf
oral pathogens and upregulate the generation of cytotoxic CD8+ T-cells that eliminate
intracellular pathogens in the oral environment.32 TH1 activity has been reported to
parallel the increase of mature DCs in the gingival tissue in periodontitis disease
states.63 Porphyromonas gingivalis is a gram negative perio-pathogenic bacteria. In
chronic periodontitis patients, P. gingivalis has been reported to stimulate mature DCs to
secrete IL12 and IFNG.64 Both cytokines can promote TH1 responses and lead to
sustained inflammation in the periodontium.63 With regard to periodontitis, IFNG is the
signature cytokine released by TH1 cells and is associated with activating phagocytosis
and the upregulation of other inflammatory cytokines and chemokines.63 TH1 responses
in the periodontium have also associated with increased receptor activator of NF-kB
ligand (RANKL) expression65 enhanced osteoclast formation, and alveolar bone loss in
vivo.66 In addition, the TH1 characteristic cytokine IFNG is presented at high levels in
periodontal disease afflicted lesions and has been shown to be linked to progressive
inflammation or more severe periodontal disease states.32
TH17 cells protect the oral environment against invading bacteria by promoting
mucosal immune responses as well as inducing bone damage.67 The characteristic
20

cytokine synthesized by TH17 cells is IL17A. TH17 cells have been shown to increase
neutrophil recruitment to the dental plaque through IL17A signaling for effective bacterial
clearance.68 When orally infected with P. gingivalis, the number of conventional DCs
increases, which has been positively correlated with the generation of a TH17 cell
response.63 Bacterial oral infection stimulates the migration of conventional DCs to the
lymph nodes and gingiva, which has been associated with upregulation in IL17A levels
and other pro-inflammatory signaling factors such as TNF, IL6, and IL1B, which
contribute to alveolar bone loss.69 In human studies, IL17A levels are also associated
with increased mature conventional DCs and increased severity of periodontal bone
loss.63 TH17 cells function as a bone damaging T-cell subset by promoting
osteoclastogenesis through the secretion of IL17A and the induction of pro-inflammatory
and osteoclastic mediators such as RANKL and TNF.67,70
In contrast to TH1 and TH17 cells, TREG cells limit excessive inflammation within
the periodontium and function to support alveolar bone homeostasis.32 In inflamed
periodontal disease states, TREG cell characteristic cytokine levels (i.e., IL10, TGFβ) have
been reported to be suppressed.71 When TREG cell function is inhibited, higher levels of
IFNG, TNF, and RANKL are expressed in the periodontium, which exacerbates
osteoclast mediated alveolar bone loss.72
TH22 cells have been extensively studied in dermal conditions, but their role in
periodontal health and disease still remains unclear.73 These cells are characterized by
high production of IL22 and low production of IL17A and IFNG.74 TH22 cells are found to
be localized in the epithelium and associated with the production of antimicrobial
peptides like defensins, which aid protection against tissue inflammation.73 Due to the
high expression of β-defensins in the gingival epithelium, TH22 cells appear to have antiinflammatory properties that support periodontal tissue homeostasis.73
21

The Novince group has previously shown that the commensal gut microbiota
modulates the host immune response at non-oral skeletal sites.75 TH17 cells,
CD4+IL17A+T-cells, and TNF were upregulated in the long bone marrow of specificpathogen-free mice (SPF) vs. germ-free (GF) mice, which reveals that the commensal gut
microbiota regulates CD4+ T-cell hematopoiesis at non-oral skeletal sites.75 Specific to the
current study, Irie, Novince, and Darvaeu (2014) have shown that the commensal oral
microbiota critically regulates osteoimmune response mechanisms in the healthy
periodontium.76 12-week-old GF vs. SPF mice were utilized to determine the commensal
oral microbiota’s osteoimmunoregulatory effects on alveolar bone homeostasis. The
burden of the commensal microbiota in SPF mice increased neutrophils, CD4+ T-cells and
IL17+ T-cells in the junctional epithelium, upregulated RANKL expression and osteoclast
cell numbers lining alveolar bone, which exacerbated linear alveolar bone loss.76 The
authors concluded that the commensal oral microbiota induction of the periodontal
immune defense response results in a low-grade basal inflammation which causes
alveolar bone loss during health.76

General background on osteoimmunology and alveolar bone homeostasis
Osteoimmunology is the study of the close interrelationship between bone and
the immune system. Osteoimmunology research has revealed that innate immunity,
adaptive immune cells, and the endocrine system play key roles in regulating skeletal
modeling (bone growth) and remodeling (bone turnover).77,78 Bone modeling directs
longitudinal skeletal growth and bone mass accrual in the developing skeleton, while
remodeling is important for the maintenance of bone mass and homeostasis of the
mature adult skeleton.37 The current research will focus on osteoimmune processes that
influence bone remodeling / turnover in the mature alveolar bone complex. Bone
22

remodeling is regulated by mesenchymal-derived osteoblasts, which secrete and
mineralize the bone matrix, and hematopoietic-derived osteoclasts, which demineralize
and resorb bone.79,80 Bone homeostasis depends upon the tightly coupled process of
bone forming osteoblasts and bone resorbing osteoclasts.79 At physiological conditions
the actions of osteoclast and osteoblasts are balanced. However, when the balance is
disturbed, bone architecture or function is compromised.79 At the molecular level, the
Tnfsf11(RANKL):Tnfrsf11b(OPG) (RANKL-OPG) axis is an important regulator of
osteoclastogenesis and bone remodeling, which has implications for skeletal
homeostasis.81
Osteoblasts are bone forming cells that are derived from the mesenchymal cell
lineage. Osteoblast lineage cells consist of osteoblast precursors, osteoblasts, bone
lining cells, and osteocytes.82,83 Osteoclasts are multinucleated bone resorbing cells that
originate from mononuclear cells derived from the hematopoietic lineage. Osteoclasts
function to resorb the bone matrix under the influence of several factors.84 The factors
essential and necessary for osteoclastogenesis are macrophage colony-stimulating
factor (CSF1) and receptor activator of nuclear factor kappa B ligand (RANKL).85,86
CSF1 is a secreted factor required for pre-osteoclastic cells to differentiate into
osteoclast precursor cells, and importantly induces the expression of the RANKL
receptor, RANK.86 RANKL signaling at the RANKL receptor drives osteoclast
differentiation, maturation, function, and survival.81,86
RANKL is a member of the tumor necrosis factor (TNF) cytokine family and plays
a critical role in periodontal bone resorption.87 The major cellular sources of RANKL in
the periodontium are B-cells and T-cells.88 RANKL expression was found mainly in
lymphocytes and macrophages within the lesions of periodontal disease afflicted
lesions.89 Osteoclast differentiation is regulated by transcription factors that are induced
23

by RANKL signaling at the RANK receptor.90 When RANKL binds to RANK on osteoclast
precursors, it causes the activation of nuclear factor for activated T-cells, cytoplasmic 1
(NFATC1).91 NFATC1 is known as the master regulator of osteoclast differentiation as it
transcribes a number of osteoclast specific genes responsible for differentiation,
maturation, and function.91 Dendritic cell specific transmembrane protein (DCSTAMP) is
an RANKL induced fusion protein critical for osteoclast maturation.92
Osteoprotegerin (OPG) functions as the RANK decoy receptor. OPG is
expressed in the bone marrow environment by stromal cells, osteoblasts, T-cells, B-cells
and DCs.84,86,93 This soluble decoy receptor binds RANKL to inhibit the interaction
between RANKL and the RANK receptor, which in turn prevents osteoclast
differentiation and function.79 Thus, the ratio of RANKL to OPG is critical when
evaluating RANKL-mediated osteoclastogenesis.
Pro-inflammatory cytokines, such as IL1B, IL17A, IL6, IFNG and TNF, have been
identified as mediators of bone resorption. These pro-resorptive cytokines can enhance
RANKL-signaling mediated osteoclastogensis.94 Early studies identified an osteoclast
activating factor produced in response to periodontal plaque bacteria, which was later
recognized as interleukin-1 (IL1).85 Within the IL1 family, IL1B upregulates the
production of RANKL, enhancing its activity and stimulating osteoclastogenesis.95,96 IL1B
also has the ability to upregulate the expression of other pro-inflammatory cytokines in
order to promote osteoclastogenesis and inhibit osteoblastogenesis.95,96 IL1B also has
synergistic effects on TNF-signaling induced osteoclastogenesis, as many proinflammatory effects of TNF on osteoclasts are upregulated by IL1B.97 IL1B is secreted
by a variety of cells consisting of macrophages, B-cells, neutrophils, fibroblasts and
epithelial cells, and has received considerable attention as a potential inflammatory
marker for active periodontal bone loss.85
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TNF has been reported to play a critical role in the pro-inflammatory immune
response, alveolar bone resorption, and loss in the attachment of connective tissue in
the periodontium.32,98 TNF is highly expressed in both the gingival crevicular fluid and
diseased periodontal tissues, in which it is positively associated with matrix
metalloproteinases (MMPs) and RANKL expression.32 In addition, experimental
periodontitis in TNF-a p55 receptor deficient mice was characterized by suppressed
RANKL and MMPs expression, which was associated with the significant reduction in
alveolar bone loss.32 TNF actions can influence and support osteoclastogenesis by
acting in concert with RANKL-signaling to promote the differentiation and function of
osteoclasts.99 TNF has also been shown to be involved in the induction of pre-osteoclast
fusion and differentiation by activating cellular autophagy, which leads to bone
resorption.100
Another important inflammatory mediator found in the periodontium, IL6, has
been characteristically associated with inflammatory cell migration and
osteoclastogenesis processes.98 IL6 has been found in the gingival crevicular fluid of
the oral cavity during the progression of periodontal destruction.101 In
immunohistochemistry studies, increased IL6 expression was present in inflamed
gingival tissue isolates102, and in tissue retrieved from periodontitis compared to gingivitis
afflicted sites.103,104 Supporting the association of IL6 expression in the inflamed gingiva,
the concentration of IL6 in gingival tissue has been reported to be increased in inflamed
compared to normal tissue from young adults.105 IL6 has been shown to inhibit
osteoclastogenesis via inducing the expression of RANKL by osteoblasts.106 One study
demonstrated that IL6 directly acts on osteoclast progenitor and inhibits their
differentiation by specifically suppressing RANKL-mediated signaling pathways.106
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The signature cytokine of the TH17 cell response, IL17A also plays a critical role
as a pro-inflammatory, pro-osteoclastic cytokine in the induction of periodontal bone
destruction.32,67 In one study, IL17A enhanced the expression of RANKL and inhibited
the expression of OPG in human periodontal ligament cells, leading to an increased
RANKL:OPG ratio, which suggests that IL17A plays a pro-catabolic role in the
pathogenesis of periodontal bone loss.107 A separate experimental study demonstrated
that IL17A deficient mice have decreased osteolytic bone lesions in response to periopathogen challenge,108 which further supports the notion that IL17A contributes to
alveolar bone resorption.
The signature cytokine of the TH1 cell response, IFNG, plays a more
controversial role in osteoclast differentiation and function.32 IFNG has been shown to
have direct anti-osteoclastogenic actions and indirect pro-osteoclastic actions, which are
dependent of the local cellular micro-environment.109 IFNG is characteristically
associated with the production of inflammatory cytokines and chemokines, and has been
shown to have actions supporting osteoclastogenesis.110-112

Composition of the healthy oral microbiota
The oral microbiota refers to the collection of microbes inhabiting the human oral
cavity.113 The oral microbiome refers to the gene complement of that community. While
each individual’s oral microbiome consists of a distinct set of microorganisms, these
microbes play an important role in maintaining the homeostatic environment within the
mouth.113 The human mouth is colonized by viruses, protozoa, fungi, archaea, and
bacteria.44 The mouth supports one of the most diverse microbial communities
compared to other sites found within the human body. This is due to its heterogeneity of
the oral microbes and the interrelationships between the different anatomical structures
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of the oral cavity.44 Microbial habitats of the oral cavity are represented by the hard
tissue (teeth), soft tissues (cheek, tongue, lip, gingival sulcus, attached gingiva, and the
hard/soft palate), and the interface of the two (subgingival and supragingival margins,
and gingival crevices around the teeth).114 The contiguous extensions of the oral cavity,
such as the tonsils, pharynx, eustachian tube, middle ear, trachea, lungs, and cervical
lymph nodes (CLNs), are also inhabited by the oral microbiota. However, the majority of
oral microbiota studies are centered on evaluating samples from the oral cavity, such as
gingiva, dental plaque, or saliva.114 Oral cavity structures are continuously humidified by
two physiological fluids, saliva and gingival crevicular fluid, which contribute to
maintaining homeostasis in the oral environment by providing water, nutrients,
antibodies, and antimicrobial and adherence factors.115
Studies have shown that different oral structures and tissues in the normal oral
microbiota are colonized by distinct microbial communities.43,116 The majority of studies
defining the composition of the oral microbiota are primarily focused on bacteria.
Approximately 280 bacterial species from the oral cavity have been isolated in culture
and formally identified.2 In the mouth, approximately half of the bacteria present are able
to be cultivated using aerobic microbiological methods, while there are likely 500 to 700
common oral species.2 Complex bacterial communities in the oral cavity have been
identified and characterized by culture-independent methods based on the analysis of
the sequences of conserved housekeeping genes, including the 16S rRNA gene.2
The bacterial community of the oral cavity is dominated by the phyla Firmicutes,
Bacteriodetes, Proteobacteria, Actinobacteria, Spirochaetes, and Fusobacteria, which
account for approximately 96% of bacterial species present.2 The precise composition of
the healthy oral microbiome is difficult to determine as the mouth is an open system and
frequently exposed to exogenous factors.2 The oral cavity can be considered as a major
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gateway to the human body.43 Food enters the mouth and is chewed and mixed with
saliva on its way to stomach and intestinal tract for digestion. Air continuously passes
through the nose and the mouth on the way to the trachea and lungs. Therefore,
microorganisms specific to one area of the oral cavity have a high probability of
migrating and spreading on contiguous epithelial surfaces to neighboring sites.43 Within
the oral environment, the highest microbiota richness has been found in gingival plaque
and saliva sites, while the lowest richness has been described in the keratinized
gingiva.117 The supragingival or subgingival tooth surfaces provide the most stable
environment for bacterial species colonizing in the oral cavity.114 These non-shedding
surfaces are covered by persisting biofilms which represent the earliest colonizers of the
teeth114.
The commensal microbiota plays an important role in maintaining oral and
systemic health.44,113 The presence of commensal microbes in the oral cavity inhibits
colonization of pathogens and invading bacteria.44 Because all surfaces of the mouth are
colonized by commensals, there are limited binding sites available for pathogens.44
While the complex equilibrium between resident species in the oral cavity is responsible
for the maintenance of a healthy state, microorganisms within the oral cavity can
become disturbed to enter a state of dysbiosis, which can lead to pro-inflammatory oral
disease states such periodontal disease.2

Antibiotic perturbation of the oral microbiota
The establishment and preservation of a symbiotic relationship with the
colonizing commensal microbiota critically supports host health.14 Extrinsic factors can
influence the composition of the commensal microbiota at distinct sites in the human
body and ultimately effect overall health.113 Studies of these microbes in the gut and oral
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cavity have uncovered important interactions between bacteria and human hosts in a
wide variety of normal and pathological states.14,118 The commensal microbiota
composition and function has been shown to be influenced by variations in host diet,
lifestyle, hygiene, or use of antibiotics.14 Unlike the host genome which is resistant to
extrinsic mediators, the microbiome is dramatically impacted by exogenous factors.14
The Novince lab has previously demonstrated that antibiotic perturbation of the
commensal gut microbiota dysregulates normal osteoimmunological processes at nonoral skeletal sites.17 A broad-spectrum antibiotic cocktail (ABX) consisting of vancomycin
(500mg/L) targeting gram-positive bacteria, imipenem/cilastatin (500mg/L) targeting
gram-positive/gram-negative bacteria and anaerobes, and neomycin (1000mg/L)
targeting gram-positive/gram-negative bacteria, was employed to broadly disrupt the
indigenous gut microbiota.17,119 Antibiotic treatment was initiated via supplementation of
drinking water to male and female C57BL/6T mice from the age of 6 to 12 weeks.17 The
experimental design in this study provided the opportunity to evaluate the antibiotic
disruption of the gut microbiota and the secondary osteoimmunomodulatory effects
during a critical window of skeletal development.17
While ABX treatment reduced the overall gut bacterial load in both male and
female mice versus sex-matched vehicle treated mice, bacterial phylum level alterations
in the gut microbiota were sex-dependent.17 ABX treated male mice had increased
Proteobacteria and decreased Bacteriodetes, whereas ABX treated female mice had
increased Proteobacteria and decreased Bacteriodetes and Firmicutes.17 Antibiotic
disruption of gut microbiota lead to impaired trabecular bone mass and microarchitecture
properties.17 ABX induced a pro-inflammatory hyperimmune response in lymphoid
tissues draining the gut, which lead to increased levels of circulating factors that
enhanced osteoclastogenesis at distant skeletal sites.17 The seminal report revealed that
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antibiotic disruption of the indigenous gut microbiota has the capacity to dysregulate
normal osteoimmune processes at non-oral skeletal sites. Currently unknown, antibiotic
perturbation of the indigenous oral microbiota may dysregulate osteoimmune
mechanisms in the alveolar bone complex which leads to deleterious effects on
periodontal health and homeostasis.
While the majority of studies on antibiotics and the microbiota are focused within
the gut, there is emerging research on the effect that antibiotics have on the oral
microbiota. Treatment with a broad spectrum antibiotic cocktail (500mg/L ampicillin,
500mg/L vancomycin, and 1g/L metronidazole) has been shown to deplete the resident
bacteria in the oral microbiota, which diminished host immune response protective
effects and exacerbated oral mucosa tissue destruction.120 The authors found that the
combination of the antibiotics in their experimental treatment diminished salivary short
chain fatty acid levels and TH17 and TREG cells in the oral mucosa, which depleted the
host immune response responsible for fungal clearance and reducing inflammation.120
Other studies on the effect of antibiotics on the oral microbiota have reported that
antibiotics such as azithromycin, amoxicillin, clindamycin, and ciprofloxacin affect the
amount and diversity of oral microbes.121,122 Abeles et al. (2016) examined the effects of
two commonly prescribed antibiotics, amoxicillin and azithromycin, to discern whether
short term antibiotic courses may have prolonged effects on the human commensal
microbiota.122 A significant change in the microbiota diversity was found in the gut and
mouth in response to antibiotics, but no analogous patterns were observed in the skin.122
Amoxicillin treatment for 7 days demonstrated greater reductions in oral microbial
diversity compared to treatment duration up to 3 days, which was in contrast to the
highly diverse oral microbiota seen at the early time point in subjects treated with
azithromycin.122 The authors concluded that as few of 3 days of treatment with
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commonly prescribed antibiotics can result in alterations in oral microbiota diversity,
which could have implications for the maintenance of human health and resilience to
disease.122 In a similar study, Zaura et al. (2015) reported that treatment with widely
used antibiotics, such as clindamycin and ciprofloxacin, have effects on the oral
microbiota.121 At the one week time point of antibiotic treatment, a microbial shift was
observed in saliva samples in response to both clindamycin and ciprofloxacin, resulting
in phylum level alterations in Proteobacteria and candidate division TM7.121 Exposure to
clindamycin resulted in the most pronounced and long-lasting change on oral microbial
profiles of salivary samples, which remained significant up to 1 month following
treatment.121

General background on minocycline
Minocycline is a potent, broad spectrum antibiotic within the tetracycline class of
antibiotics.123 Tetracyclines are bacteriostatic antibiotics considered to be broad
spectrum due to their activity against a broad range of aerobic and anaerobic grampositive and gram-negative bacteria.123 The basic chemical structure of these antibiotics
consists of a tetracyclic napthacene carboxamide ring with substituents at different
positions.124 For higher efficiency in these tetracyclines, structural changes have been
developed, such as the ring D modification through carbons 7-9 within the semi-synthetic
compounds minocycline and doxycycline.124 The mechanism of action behind the
antibiotic properties of minocycline is related to the drug’s ability to bind to the bacterial
30S ribosomal subunit and interfere with protein synthesis.123 Tetracyclines enter
bacterial cells through porin channels by coordinating with cations like magnesium and
becoming positively charged complexes.125 This complex enables tetracycline to enter
the periplasm and disassociate, which allows a lipophilic tetracycline to diffuse into
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bacterial cytoplasm.125 Tetracyclines are able to prevent aminocyl-tRNA from binding to
the 30S ribosome and inhibit protein synthesis in susceptible bacterial microbes.123,125
Minocycline has been shown to present a better pharmacokinetic profile than its parent,
tetracycline, when used orally.123 Oral minocycline administration allows rapid and
complete absorption, a longer half-life, and excellent tissue penetration with almost
complete bioavailability.123 Minocycline is the most frequently prescribed oral antibiotic
for the treatment of dermatological conditions in the United States,126 which highlights
the clinical significance of the drug. Minocycline is excreted in high concentrations in the
gingival crevicular fluid, and thus has the potential to influence the indigenous oral
microbiota.127
Tetracyclines present a high affinity for calcified tissues as they are able to bind
to calcium and form a tetracycline-calcium orthophosphate complex, which can be
deposited and persistent in osteogenic regions of bone.127 As the rate of mineralization
increases, the more tetracycline can become deposited in bone.128 These agents have
also been shown to remain in ossification zones for relatively long periods of time after
systemic administration.128 As minocycline is absorbed, minocycline becomes bound to
plasma proteins and is distributed to various tissues in the human body through blood
supply.129 Within these tissues, the antibiotic can then become oxidized and transformed
to a pigmented byproduct.129 Minocycline has been reported to cause pigmentation in a
variety of tissues, such as skin, thyroid, nails, teeth, tongue, and bone.130-132 Minocycline
pigmentation of bone is termed “black bone disease” and has been evident in a number
of cases presenting within the oral cavity.131
Minocycline has intriguingly been shown to exhibit anti-apoptotic,
immunosuppressive and anti-inflammatory properties in several pathological conditions,
including acne vulgaris, periodontitis (Arestin), rheumatoid arthritis, neural ischemic
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damage, Parkinson’s disease, and Huntington disease.133-136 A rheumatoid arthritis study
reported that CD4+ T-cells derived from the synovium of diseased patients were altered
by minocycline treatment. Minocycline disrupted activated T-cell-induced proliferation
and inflammatory cytokine production, which suggests that minocycline has
immunomodulatory effects on human cloned synovial T-cells.136
Minocycline is a potent, broad spectrum antibiotic that has a high affinity for the
bone matrix and reported biological actions independent of their antimicrobial activity,
which underscores the need to advance our understanding of the relationship between
minocycline, the oral microbiota, and osteoimmunology. This study will begin to
delineate the impact that oral antibiotic administration has on the periodontal immune
response and alveolar bone remodeling processes. The application of novel
osteoimmunology research techniques in the alveolar bone complex will provide
mechanistic insight into antibiotic effects on osteoimmune mechanisms that critically
regulate periodontal health and homeostasis.
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CHAPTER 2: MATERIALS AND METHODS
Specific-Pathogen-Free (SPF) Mice
Five-week-old murine-pathogen-free C57BL/6T mice were purchased from
Taconic Biosciences (Rensselaer, NY) and housed under SPF conditions at Medical
University of South Carolina (MUSC). Antibiotic cocktail (ABX) treatment model: Male
mice were administered a broad spectrum antibiotic cocktail [vancomycin (500mg/L),
imipenem/cilastatin (500mg/L), neomycin (1 g/L)] or vehicle control in drinking water
from age 6 weeks to 12 weeks; animals were euthanized at age 12 weeks. Minocycline
(MINO) treatment model: Sex-matched male / female mice were administered
minocycline [100mg/L] or vehicle control in drinking water from age 6 weeks to 12
weeks; animals were euthanized at age 12 weeks and at age 18 weeks. Mice were
euthanized by terminal cardiac blood draw following profound anesthesia, which was
achieved through intraperitoneal injection of ketamine (100mg/mL) and xylazine
(20mg/mL). All work with mice was approved by the MUSC Animal Protocols Review
Board and was performed in accordance with the National Institute of Health Guide for
Care and Use of Laboratory Animals.

Germ-Free (GF) Mice
GF C57BL/6T mice were acquired from Taconic Biosciences (Rensselaer, NY).
GF mice were bred and maintained in sterile isolators at MUSC Gnotobiotic Animal
Core. Minocycline (MINO) treatment model: Male mice were administered minocycline
[100mg/L] or vehicle control in drinking water from age 6 weeks to 12 weeks; animals
were euthanized at age 12 weeks. Mice were euthanized by terminal cardiac blood draw
following profound anesthesia, which was achieved through intraperitoneal injection of
ketamine (100mg/mL) and xylazine (20mg/mL). All work with mice was approved by the
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MUSC Animal Protocols Review Board and was performed in accordance with the
National Institute of Health Guide for Care and Use of Laboratory Animals.

Micro-CT
Isolated maxillae and mandibles were fixed in 10% phosphate-buffered-formalin
for 24 hours at room temperature and thereafter stored in 70% ethanol. Specimens were
scanned with Scanco Medical μCT 40 Scanner, using the following acquisition
parameters: X-ray tube potential = 70 kVp; X-ray intensity = 114 μA; Integration time =
200 ms; Isotropic voxel size = 10 μm3. Calibrated three-dimensional images were
reconstructed for analyses. A fixed threshold of 1250 Hounsfield units was utilized to
determine mineralized bone tissue for morphometric analysis.

Figure 2: Mandible Orientation for Micro-CT Analysis

Cortical and trabecular alveolar bone morphology was assessed in the
bifurcation of the mandibular first molar using AnalyzePro Analysis software (Analyze
Direct, Seattle, WA). Each specimen was consistently oriented before determining the
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region of interest (ROI) for cortical analysis and the volume of interest (VOI) for
trabecular analysis (Figure 2). The mandibular first molar was oriented in the axial plane
such that the mid-buccal lingual aspects of the mesial and distal roots were aligned to a
horizontal plane at 0 degrees. The first molar was oriented in the sagittal plane such that
the CEJ at the mesial and distal aspect of the tooth were aligned to a horizontal plane at
0 degrees (Figure 2).
Alveolar bone cortical thickness was assessed in a 200μm mesial-distal ROI, at
both the buccal cortical plate and lingual cortical plate, within the bifurcation of the
mandibular first molar. The ROI was centered at the midpoint between the mesial and
distal roots in the axial view. Cortical thickness was assessed in a 100 μm (10 slices)
region mesial to the midpoint and a 100μm (10 slices) region distal to the midpoint. Buccal
cortical plate measurements were performed via drawing a perpendicular line from the
endocortical surface to the periosteal surface of the buccal cortical plate. Lingual cortical
plate measurements were performed via drawing a perpendicular line from the
endocortical surface to the periosteal surface of the lingual cortical plate (Figure 2).
Outcomes reported include buccal cortical thickness, lingual cortical thickness, and an
average of the two sites of interest. Data are reported in accordance with standardized
nomenclature.137
Alveolar bone trabecular bone volume fraction was assessed in a defined volume
of interest (VOI), within the bifurcation of mandibular first molar. The VOI was created by
linearly morphing a cylinder within the bifurcation, excluding the periodontal ligament
lining the mesial and distal roots and the endocortical surface of the buccal and lingual
cortical plates (Figure 2). The height of the cylinder was set so that the superior aspect
of the cylinder was positioned at the fornix of the bifurcation and the inferior aspect of the
cylinder was positioned at the distal root apex (Figure 2). Fixed threshold of 1250
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Housnfield units was used in order to discriminate mineralized tissue. Outcomes
reported include bone volume per tissue volume. Data are reported in accordance with
standardized nomenclature.137

Figure 3: Maxilla Orientation for Micro-CT Analysis

Linear alveolar bone loss was assessed at the maxillary first molar using the
AnalyzePro Analysis software (Analyze Direct, Seattle, WA). Linear alveolar bone loss
was evaluated by measuring the linear distance from the CEJ to ABC, at the
mesiobuccal line angle, distobuccal line angle, and mid-lingual aspect of the maxillary
first molar (Figure 3). The CEJ to ABC measurement began at CEJ, the anatomical site
where the enamel meets the cementum, and ended at the ABC, the anatomical site
where the cortical plates merge with the alveolar bone proper.138 Reconstructed maxilla
images were consistently oriented prior to measuring the CEJ to ABC linear distance at
each anatomical line angle (Figure 3). The maxillary first molar was oriented in the axial
plane such that the mid-buccal lingual aspect of the mesiobuccal and distobuccal roots
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were aligned to a horizontal plane at 0º. The first molar was oriented in the sagittal plane
such that the CEJ at the mesial and distal aspect of the tooth were aligned to a
horizontal plane at 0 degrees (Figure 3).
Within the axial plane, the coronal height of contour was determined at the
mesiobuccal line angle, distobuccal line angle, and mid-lingual aspect of the molar.
These landmarks served as the midpoint for carrying out CEJ to ABC linear
measurements. 5 total measurements were made at each anatomical site of interest.
Measurements were made at the midpoint and +/-10 and +/-20 slices from the midpoint.
Outcomes reported for CEJ to ABC analysis consisted of an average of the five
measurements performed for each anatomical site of interest. Data are reported in
accordance with standardized nomenclature.

Histomorphometry
Maxillae were fixed in 10% phosphate-buffered-formalin for 24 hours at room
temperature. Maxillae were then decalcified in 14% ethylenediaminetraacetic acid
(EDTA) for 21 days at room temperature and submitted for paraffin embedded
histological processing. Sagittal sections were cut through the maxillary first molar.
Tartrate-resistant acid phosphatase (TRAP) stain with an aniline blue counterstain was
performed for histomorphometric analysis of osteoclast cellular endpoints. Osteoclast
were scored lining the alveolar bone within the furcation, which was contained by the
mesiobuccal root and distobuccal root. The ROI excluded the periodontal ligament
space and the basal bone. TRAP+ multinucleated (three or more nuclei) cells lining the
alveolar bone surface within the furcation were considered osteoclasts. Images were
acquired at 200x via the Nikon Eclipse TS1000 microscope (Nikon Inc., Melville, NY).
Images were stitched using Adobe Photoshop (Adobe, San Jose, CA). Blinded
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histomorphometric analysis of TRAP+ osteoclast cellular endpoints was performed using
ImageJ software (ImageJ 1.52a, NIH, Bethesda, MD). Stitched maxilla images were
analyzed at a set scale of 2.8346 pixels/mm. Osteoclast endpoints include number of
osteoclasts per bone perimeter (N.Oc/B.Pm), osteoclast area per osteoclast (Oc.Ar/Oc),
and percent osteoclast perimeter per bone perimeter (Oc.Pm/B.Pm). Data are reported
in accordance with standardized nomenclature.139

Quantitative Real-Time PCR (qRT-PCR) for 16S rDNA Analysis
DNA Extraction: Left maxillary gingiva, right / left mandibular gingiva, and right /
left buccal vestibule mucosa were isolated at sacrifice. Mucogingival isolates were flash
frozen upon collection and stored at -80°C. Deoxyribonucleic acid (DNA) was extracted
from mucogingival isolates using the DNEasy Powersoil Pro Kit (Qiagen, Hilden,
Germany). Manufacture’s protocol was modified to include additional homogenization
steps, in order to increase the quantity of eluted DNA.
PowerBead Pro tubes were briefly spun down. The mucogingival isolates were
weighed and delivered to the tubes for homogenization. Optimized homogenization
steps were performed as follows: 1) Solution CD1 was added to the PowerBead Pro
tube and vortexed for 10 minutes. 2) Using sterile sharp tweezers and 1000ul pipette,
the samples were homogenized by clamping and pulverizing the isolates against the
bottom of the PowerBead Pro tube within the CD1 solution. 3) An additional vortex for 5
minutes was required to complete the homogenization. Thereafter, DNA extraction
continued following the manufacturer’s protocol. Genomic DNA was eluted and stored at
-20°C for downstream applications.
DNA Quantification: Total DNA was quantified via NanoDrop 1000 (Thermo
Scientific, Waltham, MA). DNA was read on a spectrophotometer to determine
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concentration of DNA in ng/μL and purity of DNA at absorbance wavelength ratio of
260/280nm. Genomic DNA was then used for 16S rDNA qRT-PCR analysis evaluating
alterations in total bacterial load (universal primer) and bacterial phyla (phylum specific
primers).
16S rDNA Primers: Forward / Reverse primer sequences are reported in Table
2. All primers were ordered from Integrated DNA Technology (Integrated DNA
Technologies, Carolville, IA) and were reconstituted at a concentration of 100uM.
Table 2: 16S rDNA Primer Sequences
Bacterial gene target
Universal 16S140

Primer sequence
F: 5’- AAACTCAAAKGAATTGACGG -3’
R: 5’- CTCACRRCACGAGCTGAC -3’

α-Proteobacteria140

F: 5’- CIAGTGTAGAGGTGAAATT -3’
R: 5’- CCCCGTCAATTCCTTTGAGTT -3’

γ-Proteobacteria140

F: 5’- TCGTCAGCTCGTGTYGTGA -3’
R: 5’- CGTAAGGGCCATGATG -3’

Actinobacteria140

F: 5’- TACGGCCGCAAGGCTA -3’
R: 5’- TCRTCCCCACCTTCCTCCG -3’

Bacteroidetes140

F: 5’- CRAACAGGATTAGATACCCT -3’
R: 5’- GGTAAGGTTCCTCGCGTAT -3’

Firmicutes140

F: 5’- TGAAACTYAAAGGAATTGACG -3’
R: 5;- ACCATGCACCTGTC -3’

Fusobacteria141

F: 5’- GGATTTATTGGGCGTAAAGC -3’
R: 5’- GGCATTCCTACAAATATCTACGA -3’

Spirochaetes2

F: 5’- GAGAGTTTGATYCTGGCTCA -3’
R: 5’- GTTACGACTTCACCCTCCT-3’

16S rDNA qRT-PCR: Genomic DNA (gDNA) was amplified via the StepOnePlus
System (Applied Biosystems, Foster City, CA), SYBR Green Fast Master Mix (Applied
Biosystems), forward / reverse primers (Table 2). A 20 μL PCR reaction was performed
using 10 μL of SYBR Master Mix (2x), 6.4 μl of primers (800nM/uL), and 3.6 μL of
sample gDNA (5ng/uL). PCR samples were subjected to a 40-cycle thermocycler
protocol using the StepOnePlus System (Applied Biosystems). Cycle number 30 was
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used as the cutoff for non-specific amplification. Initial denaturing step at 95°C for 5 min,
followed by 40 cycles of 95°C for 15 min, 61.5°C for 15 min, 72°C for 20 min, ending
with a final elongation step of 72°C for 5 min.140 Relative quantification of DNA was
performed via the comparative CT method (2-ΔΔCT).142 Universal 16S outcomes are
reported relative to 12.5ug/uL of a bacterial DNA standard ladder (Microbial Community
DNA Standard; 200ng/Catalog Nos. D6306) (ZymoBIOMICS, Irvine, CA) for overall
bacterial load analysis. Phylum level outcomes were normalized to the Universal 16S
gene, and are reported as relative expression. Specimens were run in triplicate (3
technical replicates). Technical replicates were subjected to a Grubbs outlier analysis
test (α=0.05). Biological replicates were subjected to a ROUT outlier analysis test
(Q=0.5%). Replicates determined as outliers were excluded from analysis.

qRT-PCR for mRNA Analysis
Mandible Bone Marrow (MBM) Isolation: Mandibles were hemisected at the
midline, and bone marrow was isolated from the right / left mandibular ramus. A 27G x
1/2” hypodermic needle (Becton Dickinson, Franklin Lakes, NJ) attached to a 1ml
syringe was rotated through the buccal cortical plate inferior to the midpoint between the
articular surface and coronoid process and superior to the incisor canal space. The MBM
from each animal was flushed with 1.0ml of TRIzol (Invitrogen, Carlsbad, CA, USA), and
banked at -80° for subsequent processing.
Gingiva Homogenization: Gingiva isolates from each animal were submerged in
1.0ml of TRIzol reagent, and banked at -80° for subsequent processing. Gingival isolates
were thoroughly homogenized in TRIzol reagent prior to performing the RNA extraction.
Each isolate was subjected to vortexing, followed by thorough homogenization with a
1000uL pipette.
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RNA Extraction (TRIzol Method): RNA extraction of the MBM and gingival
isolates were performed using TRIzol (Invitrogen, Carlsbad, CA, USA) extraction method
via Phasemaker Separation Tubes, following manufacturer’s protocol.
Quantify RNA and cDNA Synthesis: Total RNA was quantified via NanoDrop
1000 (Thermo Scientific). Complementary deoxyribonucleic acid (cDNA) was
synthesized from RNA isolates using Taqman Random Hexamers and Reverse
Transcription Reagents (Applied Biosystems, Foster City, CA), according to
manufacturer’s protocol.
Table 3: qRT-PCR Primer-Probes
Gene target
Taqman Primer-Probe
Il1b
Mm00434228_m1
Il6
Mm00446190_m1
Il17a
Mm00439618_m1
Tnf
Mm00443258_m1
Ifng
Mm00439560_m1
S100a8
Mm00496696_g1
S100a9
Mm00656925_m1
Tnfsf11 (Rankl)
Mm00441908_m1
Tnfrsf11b (Opg)
Mm00435451_m1
Dcstamp
Mm04209236_m1
Gapdh
Mm99999915_g1

qRT-PCR gene expression analysis: Synthesized cDNA was amplified via the
StepOnePlus System (Applied Biosystems) protocol, using TaqMan Fast Advanced
qPCR Master Mix and TaqMan gene expression primer probes (Table 3). A 20 μL PCR
reaction was performed using 10 μL of Taqman MM (2x), 1 μL of primer probes (20x), 2
μL of sample cDNA (10x), and 7 μL of RNase free water. PCR samples were then
subjected to a 40-cycle thermocycler protocol using the StepOnePlus System (Applied
Biosystems); 50°C for 2 minutes, 95°C for 2 minutes, followed by 40 cycles of 95°C for 1
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second, 60°C for 20 seconds. Relative quantification of mRNA was performed via the
comparative CT method (2-ΔΔCT)142; Gapdh was utilized as an internal control gene.

Flow Cytometric Analysis
Live Cell Analysis: MBM and CLN cells were isolated, washed, and counted. Live
cells were resuspended at 100,000 cells/50uL in FACS-buffer. Cells were treated with
FcR-block (Miltenyi Biotec, Bergisch Glabach, Germany) and cell specific stains were
performed (Table 4). Dead cells were excluded from analysis by labelling with propidium
iodide viability dye (Miltenyi Biotec). Data was acquired by the MACSQuant System
(Miltenyi Biotec). Analyses were performed via FlowJo VX software (TreeStar).

43

Table 4. Flow Cytometry Live Cell Analysis
Immune Cell
Antibody
Fluorescent Tag
+
CD11b
APC
Neutrophils
Ly6CFITC
Ly6G+
VB
CD11b+
APC
Ly6GVB
Monocytes
+
F4/80
PE
Ly6C+
FITC
CD11b+
APC
M1 Macrophages
MHC II+
FITC
CD64+
APC-Vio770
+
CD11b
APC
MHC II+
FITC
M2 Macrophages
CD64APC-Vio770
CD206+
PE
CD11c+
PE-Vio770
Plasmacytoid DCs
B220+
VB
lo
MHC II
FITC
CD11c+
PE-Vio770
CD11bAPC
Conventional DCs
B220VB
MHC II+
FITC
+
CD3
PE-Vio770
CD4+ Helper T-Cells
CD8PE
CD4+
VB
CD3+
PE-Vio770
CD8PE
+
+
Naïve CD4 T-cells
CD4
VB
CD62L+
FITC
CD69APC
CD3+
PE-Vio770
CD8
PE
Activated CD4+ T+
CD4
VB
cells
CD62LFITC
CD69+
APC
+
CD3
PE-Vio770
CD8+ Cytotoxic TCD4VB
Cells
+
CD8
PE
CD3+
PE-Vio770
CD4VB
Naïve CD8+ T-cells
CD8+
PE
CD62L+
FITC
CD69APC
+
CD3
PE-Vio770
CD4VB
+
Activated CD8 TCD8+
PE
cells
CD62LFITC
CD69+
APC

Clone
REA592
REA796
1A8
REA592
1A8
REA126
REA796
REA592
REA528
REA286
REA592
REA528
REA286
MR6F3
REA754
REA755
REA528
REA754
REA592
REA755
REA528
REA641
REA601
REA604
REA641
REA601
REA604
REA828
H1.2F3
REA641
REA601
REA604
REA828
H1.2F3
REA641
REA604
REA601
REA641
REA604
REA601
REA828
H1.2F3
REA641
REA604
REA601
REA828
H1.2F3

Vendor
Milltenyi
Biotec
Milltenyi
Biotec
Milltenyi
Biotec
Milltenyi
Biotec
Milltenyi
Biotec
Milltenyi
Biotec
Milltenyi
Biotec
Milltenyi
Biotec

Milltenyi
Biotec
Milltenyi
Biotec
Milltenyi
Biotec

Milltenyi
Biotec
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Transcription Factor Analysis: MBM and CLNs cells were isolated, washed, and
counted. Cells were re-suspended at 100,000 cells/50uL in FACS-buffer. Cells were
treated with FcR-block (Miltenyi Biotec), and labeled with cell surface markers for 30
minutes. Intracellular stains were carried out following the fixation-permeabilization
buffer manufacturer’s protocol (eBioscience, Santa Clara, CA).
Fixation/Permeabilization: Cells were washed with phosphate-buffered saline (PBS) and
centrifuged for 5 minutes at 1,500 RPM at 4°C. The supernatant was aspirated and this
process was repeated for 3 washes. eFlour 780 viability dye (eBioscience) was added to
the cells and incubated at 4°C for 30 minutes, to exclude dead cells. Following
incubation, cells were washed twice via: FACS buffer added, centrifuged for 5 minutes at
1,500 RPM at 4°C, and supernatant was aspirated. Then the fixation permeabilization
solution (1 part eBioscience fixation / permeabilization concentrate + 3 parts eBioscience
fixation / permeabilization diluent) was added to the cells and plates were incubated
overnight, protected from light at 4°C. The next morning, two washes were performed
with permeabilization buffer, centrifuged for 5 minutes at 1,500 RPM at 4°C, and
supernatant was aspirated. Samples were resuspended in permeabilization buffer. The
cells were incubated with intracellular antibodies for 30 minutes at room temperature,
protected from light. Two washes were carried out with permeabilization buffer. The
samples were resuspended in FACS buffer to run for analysis. Data was acquired by the
MACSQuant System. Analyses were performed via FlowJo VX software.
TREG cells: anti-CD3-APC-Vio770 (Miltenyi Biotec, clone REA641), anti-CD4FITC (Miltenyi Biotec, clone REA604), anti-CD25-PE-Vio770 (Miltenyi Biotec,
clone 7D4), anti-FoxP3-PE (Miltenyi Biotec, clone REA788).
•

TREG Cells: CD3+CD4+CD25+FoxP3+ (% CD3+CD4+ cells)
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TH1 cells: anti-CD3-PE-Vio770 (Miltenyi Biotec, clone REA641), anti-CD4-FITC
(Miltenyi Biotec, clone REA604), anti-CD183-PE (Miltenyi Biotec, clone CXCR3173), anti-T-bet-APC (Miltenyi Biotec, clone REA102).
•

TH1 Cells: CD3+CD4+CD183+T-BET+ (% CD3+CD4+ cells)

TH17 / TH22 cells: anti-CD3-APC-Vio770 (Miltenyi Biotec, clone REA641), antiCD4-FITC (Miltenyi Biotec, clone REA604), anti-CD196-PE (Miltenyi Biotec,
clone REA277), anti-RORγt-APC (Miltenyi Biotec, clone REA278), anti-AHR-PEVio770 (eBioscience, clone 4MEJJ).
•

TH17 Cells: CD3+CD4+CD196+RORγt+AHR- (% CD3+CD4+ cells)

•

TH22 Cells: CD3+CD4+CD196+RORγt-AHR+ (% CD3+CD4+ cells)

In Vitro Osteoclast Assays
Right and left mandible marrow were flushed with 1mL a-MEM media, 10% FBS
(Hyclone), 1% PSG utilizing a 27G needle and 1ml syringe and plated in a 48 well plate.
Whole marrow cultures were incubated overnight. The following morning, non-adherent
hematopoietic cells were isolated for in vitro osteoclastogenesis assays. Cells were
plated in 96 well plates and primed for 36 hours in a-MEM media, 10% FBS (Hyclone),
1% PSG, supplemented with 10ng/mL CSF1 (R&D Systems, Minneapolis, MN). Cultures
were subsequently stimulated with control (25ng/ml CSF1 and 50 ng/mL RANKL; R&D
Systems) or minocycline treatment (0.125ug/ml minocycline (Sigma-Aldrich, St. Louis,
MO), 25 ng/mL CSF1, and 50ng/mL RANKL). The media was changed every other day
for 6 days. Day 6 control and treatment cultures were stained via the TRAP method.
Images were acquired at 100x magnification via a Nikon Eclipse TS100 microscope.
TRAP stain assay was carried out in triplicate (technical replicate) culture wells; four
images per sample were methodically acquired in the same locations within the culture
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wells. The image locations were designated at north/south/east/west and accounted for
0.166cm2 of the 0.32 cm2 total surface area per well. Osteoclast cellular outcomes
(TRAP+ cells with 3 nuclei were scored as osteoclasts) were evaluated within four fields
of view per well at 100x magnification. Cytomorphometric analysis of TRAP+ osteoclast
cells was performed using ImageJ software, version 1.51a, (NIH, Bethesada, MD, USA).
Osteoclast outcomes included number of osteoclasts (N.Oc), average osteoclast area
(Oc.Ar/Oc), and nuclei number per osteoclast (N.Nc/Oc).

Faxitron Micro-Radiographs / Gross Clinical Photos
Isolated mandibles were fixed in 10% phosphate-buffered-formalin for 24 hours
at room temperature and then stored in 70% ethanol. Two-dimensional X-ray images
were acquired using a Faxitron Microradiograph (Faxitron LX-60, Faxtiron X-ray
Corporation, Tucson, Arizona) for qualitative radiographic analysis. Mandibles
specimens were oriented uniformly with the buccal aspect facing down; X-ray exposure
time was 40 seconds with an X-ray beam energy of 36 kV. The micro-radiographs were
developed using a Medical Film Processor (Konica SRX-101A, Konica Minolta Medical &
Graphic, Inc., NJ, USA). Gross clinical photos were acquired using an Olympus SZ61
Compact Stereo Microscope (Olympus Life Sciences, Waltham, Massachusetts) with an
Infinity 2 camera (Version 5.0.3, Lumenera Corporation, Ottawa, Canada) and Infinity
Analyze imaging software (Lumenera).

Statistical Analysis
Unpaired t tests were performed using Graphpad Prism 8.0 (GraphPad, La Jolla,
CA, USA). Data are presented as mean ± SEM. Significant is indicated as *p < 0.050,
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**p < 0.010, ***p < 0.001. Power analysis consultation was carried out with the
Biostatistical Unit of the Medical University of South Carolina Bioinformatics Core.
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CHAPTER 3: RESULTS
3.1 Aim 1 Results
Studies investigating the commensal microbiota’s role in immunity have shown
that microbial communities at tissue-specific sites play important roles in prompting the
immune system, which can have secondary effects on tissue homeostasis. The
commensal oral microbiota is an emerging topic in osteoimmmunology research and has
recently been shown to play a key role in regulating alveolar bone homeostasis in the
healthy periodontium.5,6,67,76
Previous studies in the Novince Research Lab have shown an association
between the antibiotic perturbation of gut microbiota and dysregulated bone
modeling/remodeling at non-oral skeletal sites.17 To broadly disrupt the indigenous gut
microbiota, a broad spectrum antibiotic cocktail was orally administered to C57BL/6T
sex-matched mice from 6 weeks of age until euthanization at age 12 weeks.17 16S rDNA
qRT-PCR analysis revealed that antibiotic perturbation of indigenous gut microbiota had
sex dependent effects on the composition of bacterial communities at the phyla level.17
Male antibiotic treated mice were found to have higher levels of α-Proteobacteria and γProteobacteria communities and lower levels of Bacteriodetes, while female antibiotic
treated mice showed increases in α-Proteobacteria and decreases in Bacteriodetes and
Firmicutes communities.17 Furthermore, micro-CT analysis showed that antibiotic
disruption of gut microbiota induced sex dependent tissue level alterations in bone
mineral density and trabecular bone morphology at non-oral skeletal sites.17
Irie, Novince, and Darvaeu (2014) have shown that the commensal oral
microbiota has an impact on alveolar bone homeostasis.76 Utilizing the specificpathogen-free (SPF) vs. germ-free (GF) mouse model, this investigation began to
elucidate osteoimmune mechanisms regulating the oral microbiota’s impact on alveolar
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bone homeostasis during health.76 Through histomorphometric analysis of the distance
from CEJ to ABC, the commensal bacteria were shown to increase linear alveolar bone
loss in the maxillary molars of SPF vs. GF mice.4 This was the first known
histomorphometric study to discern upregulated osteoimmune mechanisms and
exacerbated alveolar bone loss SPF vs. GF mice.76
Tsukasaki et al. (2018) have recently shown that bone damaging T-cells impact
the host defense against oral microbiota by regulating protection against bacterial
infection and induction of bone destruction in the oral cavity.67 In this periodontitis model,
silk ligature placement around the maxillary second molar lead to an accumulation of
oral bacteria, which caused inflammation and bone destruction.67 Utilizing 16S sequence
analysis, the total amount of bacterial DNA was increased and the composition of oral
bacteria was altered in Il17a-/-Il17f-/- double knockout mice.67 These results suggest that
TH17 cells play a key role in the host defense against invasion of oral bacteria through
the induction of alveolar bone loss.67
Considering the previous studies from the Novince lab investigating antibiotic
perturbation of the gut microbiota17 and the oral commensal microbiota impact on
alveolar bone loss,4-6,67 the oral microbiota composition and linear alveolar bone loss
were evaluated in response to treatment with an oral antibiotic therapy, specifically
minocycline.
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Aim 1: Evaluate the persistence of minocycline induced changes in the oral microbiome
and alveolar bone homeostasis.

Figure 4. Experimental timeline of minocycline
antibiotic treatment in vivo (Aim1).

Minocycline or vehicle control treatment was supplemented to the drinking water
of sex-matched C57BL/6T SPF mice from age 6 to 12 weeks (Figure 4). Minocycline in
vivo treatment was orally administered in drinking water at a clinically relevant dose of
100mg/L. Based on the human pediatric dosage of minocycline prescribed per day to
adolescents for treatment of acne (2.0mg/kg), the mouse equivalent dosage of
minocycline treatment is 24.6mg/kg.143 Based on a 20g mouse, the amount of
minocycline the mice would receive per day is 0.492 mg (0.02kg mouse x 24.6mg/kg).
On average, a mouse consumes 4.92 mL of water per day, thus the concentration of
minocycline in drinking water to receive a human equivalent dosage is 0.1mg/mL
(100mg/L).144 Treatment was initiated at the age of 6 weeks, the developmental age
when C57BL/6T mice immune system is considered mature.145,146 Also at the 6-week
time point, the murine teeth have fully erupted and alveolar bone formation is considered
complete.33,147 Mice were euthanized at 12 weeks of age to assess the immediate impact
of minocycline treatment effects on the oral microbiome and alveolar bone homeostasis.
Other groups of mice were taken off minocycline treatment at 12 weeks of age, and
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aged to 18 weeks to allow for a 6-week recovery period of no antibiotic treatment
(Figure 4). Mice were euthanized at 18-weeks of age to assess persistent minocycline
effects on the oral microbiome and alveolar bone homeostasis. This experimental model
provides the opportunity to evaluate sex-dependent alterations and the persistence of
minocycline treatment effects on the oral microbiome and alveolar bone homeostasis
(Figure 4).
16S rDNA qPCR analysis of gingival isolates was performed to determine
minocycline perturbation of overall bacterial load and phylum level alterations in the oral
bacteriome, in male (Figure 5) and female mice (Figure 6). MINO vs. VEH treatment
caused a 20X fold increase in total bacterial load (Figure 5a) and caused phylum level
alterations (Figure 5b) in male mice at age 12-weeks immediately following 6 weeks
MINO treatment. 12-week-old male MINO vs. VEH mice demonstrated a significant
increase in Proteobacteria, a significant decrease in Firmicutes, and a trending decrease
in Actinobacteria bacteria communities (Figure 5b). MINO vs. VEH treatment caused a
sustained disruption of the oral microbiota at age 18 weeks, following the 6-week
window of recovery after the withdrawal of minocycline treatment (Figure 5c-d). While
there was no difference in the overall bacterial load (Figure 5c), 18-week-old male
MINO vs. VEH mice demonstrated significant increases in Actinobacteria and Firmicutes
bacteria communities (Figure 5d).
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Figure 5: Minocycline (MINO) perturbation of oral microbiota
composition in male mice. (a-d) 16S rDNA analysis of gingival isolates.
(a,c) Universal 16S gene analysis for total bacterial load in (a) 12-week-old
and (c) 18-week-old male mice; reported relative to 12.5ng/ul DNA Standard
-ΔΔCT
via the comparative CT method ( 2
). (c-d) Phylum-level gene analysis in
(b) 12-week-old and (d) 18-week-old male mice; reported relative to
universal 16S gene expression via the comparative CT method (2-∆∆CT).
Unpaired t-test statistical analysis was used. Data are expressed as mean ±
SEM. (n=5-6/pg) *p<0.05 vs. VEH. **p<0.01 vs. VEH. ***p<0.001 vs. VEH.

Overall bacterial load and phylum level alterations in MINO vs. VEH treated mice
were sex dependent (Figure 6). Contrary to male mice, 12-week-old female MINO vs.
VEH mice showed no differences in overall bacterial load (Figure 6a) or phylum level
alterations (Figure 6b). Demonstrating that minocycline continued to have no effect on
the oral microbiota of female mice after withdrawal of antibiotic treatment, 18-week-old
female MINO vs. VEH mice also showed no differences in overall bacterial load (Figure
6c) or phylum level alterations (Figure 6d).
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Figure 6: Minocycline (MINO) perturbation of oral microbiota
composition in female mice. (a-d) 16S rDNA analysis of gingival isolates.
(a,c) Universal 16S gene analysis for total bacterial load in (a) 12-week-old
and (c) 18-week-old female mice; reported relative to 12.5ng/ul DNA
-ΔΔCT
Standard via the comparative CT method (2
). (b,d) Phylum-level gene
analysis in (b) 12-week-old and (d) 18-week-old female mice; reported
relative to universal 16S gene expression via the comparative CT method (2∆∆CT). Unpaired t-test statistical analysis was used. Data are expressed as
mean ± SEM. (n=5-6/pg) *p<0.05 vs. VEH.
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Micro-CT analysis of linear alveolar bone loss was executed in the maxillary first
molar of male and female mice (Figure 7-8). Linear measurements assessing the
distance from CEJ to ABC were made at the mesiobuccal, mid-lingual, and distobuccal
line angles. Male MINO vs. VEH treatment demonstrated an increase in linear alveolar
bone loss at all three anatomic landmarks at age 12 weeks (Figure 7a,c). At the 18week time point in male mice, minocycline-induced alveolar bone loss was sustained
after the 6-week window of recovery following the withdrawal of antibiotic treatment. The
sustained increase in alveolar bone loss was found at the mesiobuccal and mid-lingual
line angle of the maxillary first molar, in 18-week-old male MINO vs. VEH treated mice
(Figure 7b,d).

Figure 7: Minocycline (MINO) effects on linear alveolar loss bone in male mice. 12week-old and 18-week-old, male VEH vs. MINO mice were euthanized and maxillae were
harvested for micro-CT analysis. (a-d) Linear alveolar bone loss was assessed in the
maxillary first molar via measurements of the distance from the CEJ-ABC at
mesiobuccal, mid-lingual, and distobuccal line angles. (a-b) Representative images of
CEJ-ABC measurements at mesiobuccal, mid-lingual, and distobuccal line angles in 12week-old (a) and 18-week-old (b) male mice. (c) Alveolar bone loss outcomes in 12week-old male mice. (d) Alveolar bone loss outcomes in 18-week-old male mice.
Unpaired t-test statistical analysis was used. Data are reported as mean ± SEM. *p<0.05
vs. VEH. **p<0.01 vs. VEH. ***p<0.001 vs. VEH.
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MINO vs. VEH treatment demonstrated an increase in linear alveolar bone loss,
specifically at the mesiobuccal and mid-lingual line angles, in 12-week-old female mice
(Figure 8a,c). At the 18-week time point in female mice, minocycline-induced alveolar
bone loss was sustained after the 6-week window of recovery following the withdrawal of
antibiotic treatment. MINO vs. VEH treatment demonstrated a sustained increase in
alveolar bone loss, specifically at the mesiobuccal line angle, in 18-week-old female
mice (Figure 8b,d). While no differences were detected at the distobuccal line angle at
the 12-week time point, an increase in alveolar bone loss was seen at this anatomical
site in the 18-week-old female mice (Figure 8b,d).

Figure 8. Minocycline (MINO) effects on linear alveolar bone loss in female mice. 12week-old and 18-week-old, female VEH vs. MINO mice were euthanized and maxillae were
harvested for micro-CT analysis. (a-d) Linear alveolar bone loss was assessed in the maxillary
first molar via measurements of the distance from the CEJ-ABC at mesiobuccal, mid-lingual,
and distobuccal line angles. (a-b) Representative images of CEJ-ABC measurements at
mesiobuccal, mid-lingual, and distobuccal line angles in 12-week-old (a) and 18-week-old (b)
female mice. (c) Alveolar bone loss outcomes in 12-week-old female mice. (d) Alveolar bone
loss outcomes in 18-week-old female mice. Unpaired t-test statistical analysis was used. Data
are reported as mean ± SEM. *p<0.05 vs. VEH. **p<0.01 vs. VEH.
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To validate that antibiotic perturbation of oral microbiota drives the alveolar bone
loss found in SPF mice, germ-free (GF) mice were utilized to investigate the direct effect
of minocycline on linear alveolar bone loss under the complete absence of the
microbiota. Micro-CT analysis of linear alveolar bone loss was assessed at the maxillary
first molar of 12-week-old male GF mice (Figure 9). Linear measurements assessing the
distance from CEJ to ABC were made at the mesiobuccal, mid-lingual, and distobuccal
line angles. MINO vs. VEH treatment demonstrated no differences in the linear distance
from CEJ to ABC in 12-week-old GF mice (Figure 9).

Figure 9. Minocycline (MINO) effects on linear alveolar loss bone in GF mice. 12-weekold male VEH vs. MINO treated GF mice were euthanized and maxillae were harvested for
micro-CT analysis. (a-b) Linear alveolar bone loss was assessed in the maxillary first molar
via measurements of the distance from the CEJ-ABC at mesiobuccal, mid-lingual, and
distobuccal line angles. (a) Representative images of CEJ-ABC measurements at
mesiobuccal, mid-lingual, and distobuccal line angles in 12-week-old GF mice. (b) Alveolar
bone loss outcomes in 12-week-old GF mice. Unpaired t-test statistical analysis was used.
Data are reported as mean ± SEM. *p<0.05 vs. VEH.
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3.2 Aim 2 Results
The Novince Lab has shown previously that antibiotic disruption of the gut
microbiota dysregulates osteoimmune cross talk at non-oral skeletal sites.17 These
studies utilized a broad-spectrum antibiotic cocktail (ABX) in C57BL/6T mice to
investigate exogenous perturbation of commensal gut microbiota osteoimmune effects
on osteoblastogenesis and osteoclastogenesis in the late growing skeleton.17 In ABX
treated mice, antibiotic alteration of gut microbiota increased osteoclastogenesis,
enhanced local and systemic pro-inflammatory cytokines, and altered innate and
adaptive immune cells at non-oral skeletal sites.17 Through micro-CT analysis, antibiotic
disruption of the gut microbiota induced a more profound inferior trabecular bone
phenotype in proximal tibia of male mice compared to female mice.17 Histomorphometric
analysis of proximal tibia revealed an increase in osteoclast perimeter per bone
perimeter, osteoclast size, and number of osteoclasts in ABX treated mice.17 Flow
cytometry revealed that antibiotic disruption of gut microbiota altered the innate and
adaptive immune cell profile in gut draining lymphoid tissues and the bone marrow of
non-oral skeletal sites.17
Irie, Novince, and Darveau (2014) have shown that homeostasis of healthy
periodontal tissues is impacted by innate and adaptive immunosurveillance mechanisms
in response to the commensal oral microbiota.4 The indigenous oral microbiota was
reported to cause an exacerbated naturally occurring alveolar bone loss, which was
attributed to an increase in osteoclastic cell numbers lining the surface of alveolar bone.4
To elucidate the mechanisms causing the loss of alveolar bone, the commensal oral
flora was shown to drive a host immune response through an increase in CD3+ Tlymphocytes, CD4+ helper T-cells, IL17A+ T-cells, and enhanced RANKL expression in
barrier periodontal tissues.4
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While the effect of antibiotics on commensal gut microbiota has been shown to
critically regulate osteoclast/osteoblast mediated bone metabolism at non-oral skeletal
sites, antibiotic perturbation of oral commensal microbiota has unclear effects on the
osteoimmune mechanisms regulating alveolar bone metabolism.17

Aim 2: Evaluate antibiotic treatment effects on skeletal homeostasis and osteoimmune
response mechanisms within the alveolar bone complex.

Figure 10. Experimental timeline of minocycline antibiotic
treatment in vivo (Aim 2).

In order to evaluate antibiotic induced changes in osteoimmune response
pathways, minocycline antibiotic (MINO) treatment or vehicle-control (VEH) treatment
was orally administered via supplementation of drinking water to male C57BL/6T SPF
mice, from age 6 to 12 weeks (Fig 10). Mice were administered minocycline at a human
equivalent dose, as previously described. Treatment was initiated at 6 weeks of age, the
developmental age when the murine immune system is considered principally complete
in the C57BL/6 mouse.145,146 Also at 6 weeks of age, C57BL/6 mice have reached their
stage of development where the teeth have fully erupted and alveolar bone formation is
complete.33,147 Mice were euthanized at 12 weeks of age to evaluate antibiotic-induced
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alterations in alveolar bone morphology, osteoclastogenesis, and osteoimmune
response effects.
Micro-CT analysis (Figure 11) was performed in the mandibular first molar
furcation to assess antibiotic induced tissue level alterations in trabecular and cortical
bone within the alveolar bone complex. Trabecular bone volume fraction was similar in
MINO vs. VEH treated mice (Figure 11a-b). To the contrary, minocycline treatment
suppressed cortical bone thickness at the buccal cortical plate (Figure 11c,e) and
lingual cortical plate (Figure 11d,f) of the mandibular first molar. Furthermore, combined
analysis at the buccal and lingual cortical plate analyses supported a decreased total
cortical bone thickness in MINO vs. VEH treated mice (Figure 11g).
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Figure 11. Minocycline (MINO) effects on cortical and trabecular bone
microarchitecture. 12-week-old male VEH- and MINO-treated mice were
euthanized, and mandibles were harvested for micro-CT analysis. (a-b) Micro-CT
analysis of trabecular bone in mandibular first molar furcation. (n=4-6/pg) (a)
Representative images of trabecular bone volume fraction using cylindrical method
(*region of interest defined by yellow cylinder). (b) BV/TV = trabecular bone volume
fraction. (c-g) Micro-CT analysis of cortical bone in mandibular first molar (n=4-6/gp).
(c) Representative images of cortical bone thickness at the buccal aspect of inner
cortical bone surface (*measurement of interest defined by red perpendicular dashed
line). Magnified images were set at 235% Scale Height. (d) Representative images of
cortical bone thickness at the lingual aspect of inner cortical bone surface
(*measurement of interest defined by yellow perpendicular dashed line). Magnified
images were set at 235% Scale Height. Ct.Th = cortical bone thickness outcomes at
the (e) buccal cortical plate, (f) lingual cortical plate, and (g) combined average of the
buccal / lingual cortical plates. Unpaired t-test statistical analysis was used. Data re
reported as mean ± SEM. *p<0.05 vs. VEH. **p<0.01 vs. VEH.
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Appreciating that alveolar bone loss is driven by osteoclastic bone resorption
actions, studies were performed to investigate the impact of minocycline treatment
effects on osteoclastogenesis. Histomorphometric analysis of tartrate-resistant acid
phosphatase (TRAP) stained maxilla sections was utilized to investigate the effect of
minocycline treatment on osteoclast cell outcomes in the maxillary first molar furcation.
MINO vs. VEH treated mice had significantly greater osteoclast perimeter per bone
perimeter (Figure 12e), which was attributed to enhanced osteoclast size per osteoclast
(Figure 12d). The minocycline-induced increase in osteoclastogenesis in situ, parallels

Figure 12. Minocycline (MINO) effects on in situ osteoclastogenesis.12-week-old
male VEH- and MINO-treated mice were euthanized, and maxilla harvested for
histomorphometric analysis. Histomorphometric analysis of osteoclast cellular endpoints
were performed in the trabecular bone marrow furcation of tartrate-resistant acid
phosphatase (TRAP) stained maxillary first molar sections; TRAP+ cells lining bone with
≥ 3 nuclei were designated an osteoclast. (a-b) Representative images of furcation
region of interest in TRAP-stained maxilla sections. (c) N.OC / B.Pm = osteoclast number
per bone perimeter. (d) Oc.Ar / Oc = average osteoclast area. (e) Oc.Pm / B.Pm =
osteoclast perimeter per bone perimeter. Unpaired t-test statistical analysis was
used. Data are reported as mean + SEM. **p<0.01 vs. VEH. ***p<0.001 vs. VEH.
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the minocycline-induced inferior cortical bone phenotype found through micro-CT
analysis (Figure 11c-g).
Recognizing that innate and adaptive immune cells are critical regulators of
osteoclastogeneis and inflammatory bone loss77,78,148,149, investigation of immune cell
profiles was carried out in primary and secondary lymphoid tissues drining the oral
cavity. MBM and CLN cells were isolated for flow cytometric analysis (Figure 13-15).
Innate and adaptive immune cell populations investigated were based on prior research
demonstrating the role of specific immune cells in osteoclast mediated periodontal bone
loss.
Neutrophils, monocytes, macrophages, and DCs are innate immune cell
mediators that play important roles in periodontal health and disease.150-153 Therefore,
antibiotic treatment effects on these innate immune cell populations were assessed
(Figure 13). Increased %CD11b+Ly6C loLy6G+ neutrophils were observed in the CLNs of
MINO vs. VEH mice (Figure 13a). While neutrophils were similar in the MBM (Figure
13a), %CD11b+Ly6G-F4/80+Ly6C+ inflammatory monocytes were decreased in the MBM
of MINO vs. VEH mice (Figure 13b). No differences were found in
%CD11b+MHCII+CD4-CD206+ anti-inflammatory M2 macrophages (Figure 13d),
however, %CD11b+MHCII+CD64+ pro-inflammatory M1 macrophages were decreased in
the MBM of MINO vs. VEH mice (Figure 13c). %CD11c+B220+MHCII lo pro-inflammatory
plasmacytoid DCs showed a significant increase in the MBM and CLNs in response to
MINO treatment (Figure 13e). Conversely, %CD11c+CD11b-B220-MHCII+ conventional
DCs were decreased in the CLNs and increased in the MBM of MINO vs. VEH mice
(Figure 13f).
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Figure 13. Minocycline (MINO) effects on innate immune cells in
mandible bone marrow (MBM) and cervical lymph node (CLN). 12-weekold male VEH- and MINO-treated mice were euthanized; MBM and CLN cells
were isolated for flow cytometric analysis (n=4-6/gp). (a-d) Neutrophil,
monocyte, and macrophage subsets are expressed relative to the CD11b+ cell
+
lo
+
+
population; (a) %CD11b Ly6C Ly6G neutrophils; (b) %CD11b Ly6G
+
+
+
+
+
F4/80 Ly6C inflammatory monocytes; (c) %CD11b MHCII CD64 M1+
+
macrophages; (d) %CD11b MHCII M2-macrophages. (e-f) Dendritic cell (DC)
subsets are expressed relative to the CD11c+ cell population; (e)
+
+
lo
+
+
CD11c B220 MHCII
plasmacytoid DCs; (f) CD11c CD11b B220 MHCII
conventional DCs. Unpaired t-test statistical analysis was used. Data are
reported as mean ± SEM, *p<0.05 vs. VEH, **p<0.01 vs. VEH, ***p<0.001 vs.
VEH.

Prior research has discerned that CD4+ helper T-cells and CD8+ cytoxic T-cells
regulate alveolar bone homeostasis and periodontal bone loss.12,154-157 Therefore, flow
cytometric analysis was employed to evaluate total and activated vs. naïve CD4+ T-cell
and CD8+ T-cell populations. While no differences were seen in Total CD4+ T-cells
(Figure 14a), MINO treatment caused an increase in CD3+CD8-CD4+CD62L+CD6964

naïve CD4+ T-cells (Figure 14b) and a decrease in CD3+CD8-CD4+CD62L-CD69+
activated CD4+ T-cells in CLNs (Figure 14c). No differences were seen in the MBM of
naïve and activated CD4+ T-cell populations in MINO vs. VEH mice (Figure 14b-c).
While no differences were seen in Total CD8+ T-cell (Figure 14d), MINO treatment
caused a trending increase towards significance in naïve CD8+ T-cells in the MBM and
CLNs (Figure 14e). No differences were seen in activated CD8+ T-cell populations in the
MBM, however, a trend towards a decrease in the CLNs of MINO vs. VEH mice (Figure
14f).

Figure 14. Minocycline (MINO) effects on Total, Naïve, and Activated T-cells in
mandible bone marrow (MBM) and cervical lymph nodes (CLNs). 12-week-old male
VEH- and MINO-treated mice were euthanized; MBM and CLN cells were isolated for flow
+
+
cytometric analysis (n=4-6/gp). (a-c) Helper CD4 T-cell subset composition. (a) CD3 CD8
+
+
+
+
CD4 Total CD4 Helper T-cells; (b) CD3 CD8 CD4 CD62L CD69 Naïve CD4 T-cells; (c)
+
+
+
+
CD3 CD8 CD4 CD62L CD69 Activated CD4 T-cells. (d-f) Helper CD8 T-cell subset
+
+
+
+
+
+
composition. (d) CD3 CD4 CD8 Helper CD8 T-cells; (e) CD3 CD4 CD8 CD62L CD69
+
+
+
Naïve CD8 T-cells; (f) CD3 CD4 CD8 CD62L CD69 Activated CD8 T-cells. Data are
expressed relative to CD3+CD4+ cells. Unpaired t-test statistical analysis was used. Data
are reported as mean ± SEM, *p<0.05 vs. VEH.

Due to the majority of periodontitis studies focused on the association of CD4+ Tcell mediated host immune response and alveolar bone loss12,154,158, CD4+ helper T-cell
subsets were assessed in the local MBM environment and CLNs draining the oral cavity
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(Figure 15). There were no differences in anti-inflammatory TREG cell populations in the
MBM or CLNs of MINO vs. VEH mice (Figure 15a). However, there was a significant
decrease in anti-inflammatory TH22 cell populations in the MBM and a significant
increase in CLNs of MINO vs. VEH mice (Figure 15b). To the contrary, pro-inflammatory
CD3+CD4+CD183+T-bet+ TH1 cell and CD3+CD4+RORyt+AHR- TH17 cell populations
were upregulated within the MBM and CLNs of MINO vs. VEH treated mice (Figure 15cd). Critical to the current study, the increase in pro-inflammatory TH1 and TH17 cell
populations in the MBM and CLNs appears to contribute to the pro-inflammatory

TREG cells

response seen in the oral environment secondary to minocycline treatment.

Figure 15. Minocycline (MINO) effects on CD4+ Helper T-cell subsets in mandible
bone marrow (MBM) and cervical lymph nodes (CLNs). 12-week-old male VEH and
MINO-treated mice were euthanized; MBM and CLN cells were isolated for flow
+
cytometric analysis (n=4-6/gp). (a-d) CD4 T-cell subsets composition (a)
+
+
+
+
+
+
CD3 CD4 CD25 FoxP3 TREG cells; (b) CD3 CD4 RORyt AHR+ TH22 cells (c)
+
+
+
+
+
+
+
CD3 CD4 CD183 T-bet TH1 cells; (d) CD3 CD4 RORyt AHR TH17 cells. Percentages
+
+
relative to total CD3 CD4 T-cells. Unpaired t-test statistical analysis was used. Data
are reported as mean ± SEM. *p<0.05 vs. VEH. **p<0.01 vs. VEH. ***p<0.001 vs. VEH.
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Osteoclast mediated bone resorption is promoted by pro-inflammatory
cytokines.77,81,86,159 Therefore, it was necessary to investigate pro-inflammatory cytokines
known to enhance osteoclastogenesis. Gene expression analysis was carried out to
evaluate pro-inflammatory/pro-osteoclastic factors known to be upregulated in the barrier
gingival tissue of periodontal disease afflicted sites.160 There were no significant
differences in characteristic pro-inflammatory/pro-osteoclastic cytokines in the gingiva of
MINO vs. VEH treated mice (Figure 16).

Figure 16. Minocycline (MINO) effects on pro-inflammatory mediators in mandible
gingiva. 12-week-old male VEH and MINO treated mice were euthanized and gingiva was
isolated for qRT-PCR gene expression analysis (n=4-12/gp). (a) Il1b mRNA (pleiotropic
inflammatory cytokine); (b) Il6 mRNA (pleiotropic inflammatory cytokine); (c) Il17 mRNA
(TH17 cytokine); (d) Tnf mRNA (pleiotropic inflammatory cytokine); (e) Ifng mRNA (TH1
cytokine); (f) S100A8 mRNA (neutrophil/monocyte cytokine); (g) S100A9 mRNA
(neutrophil/monocyte cytokine). Relative quantification of mRNA was performed via the
-ΔΔCT
comparative CT method ( 2
); Rn18s was utilized as an internal control gene. Data are

reported as mean ± SEM. *p<0.05 vs. VEH.

The RANKL:OPG axis, along with pro-osteoclastic signaling factors, was
investigated in the MBM to determine whether changes in critical osteoclastic genes
regulate the pro-osteoclastic phenotype found in minocycline treated mice (Figure 12).
RANKL, which signals to the RANK receptor on pre-osteoclastic and osteoclastic cells,
is necessary for the differentiation and function of osteoclasts. Osteoprotegerin (OPG)
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functions as the RANK decoy receptor by binding RANKL, preventing signaling at the
RANK receptor. Therefore, the RANKL/OPG ratio must be assessed when evaluating
potential alterations in RANKL-mediated osteoclastogenesis.77,81,86,159 DCSTAMP is the
surface protein critical for osteoclast fusion and maturation.92 There were no significant
differences in pro-osteoclastic signaling mediators or the RANKL:OPG ratio in the MBM
of MINO vs. VEH treated mice (Figure 17).

Figure 17. Minocycline (MINO) effects on pro-osteoclastic factors in mandible bone
(MB) marrow. 12-week-old, male VEH vs. MINO mice were euthanized and mandible
marrow was flushed in TRIzol for gene expression analysis. qRT-gene expression
analysis (n=6/gp): (a) RANKL mRNA; (b) OPG mRNA; (c) RANKL/OPG ratio; (d)
Dcstamp mRNA. Relative quantification of mRNA was performed via the comparative C T
-ΔΔCT
method (2
); Gapdh was utilized as an internal control gene. Data are reported as
mean ± SEM. *p<0.05 vs. VEH.

To further investigate the pro-osteoclastic effect of minocycline on alveolar bone,
additional in vitro studies were performed to investigate osteoclast outcomes in MBM cell
cultures exogenously treated with minocycline (Figure 18). TRAP+ cytomorphometric
analysis revealed a significant increase in osteoclast size (Figure 18c) and a trending
increase in number of nuclei per osteoclast (Figure 18d) in MINO vs. VEH in vitro
cultures. Both osteoclast size and number of nuclei per osteoclast are surrogate
readouts for osteoclast maturation. While the osteoclast maturation phenotype was
increased (Figure 18c,d), no differences were seen in number of osteoclast per field
(Figure 18b) in MINO vs. VEH treated cultures.
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Figure 18. Exogenous in vitro minocycline (MINO) treatment in mandible bone marrow
derived osteoclastic cell cultures. Non-adherent bone marrow cell cultures were isolated
from 12-week-old wild-type C57BL/6T mice and stimulated with 25ng/mL macrophage
colony stimulated factor (M-CSF) and 50ng/uL RANKL to induce osteoclastogenesis.
Stimulated cultures were treated with vehicle control or minocycline (0.125 µg/ml) until day
6. TRAP+ cytomorphometric analysis of osteoclast cellular outcomes was assessed in
exogenously treated minocycline (MINO) vs. vehicle-control (VEH) in vitro cultures; TRAP+
cells with ≥ 3 nuclei scored as an osteoclast. (a) Representative images of VEH and MINO
3
treated in vitro cultures. (b) N.Oc/Field = number of osteoclast per field. (c) Oc.Ar/Oc (x10 )
= average osteoclast area. (d) N.Nc/Oc = number of nuclei per osteoclast. Unpaired t-test
statistical analysis was used. Data are reported as mean ± SEM. *p<0.05 vs. VEH.
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CHAPTER 4: DISCUSSION AND CONCLUSIONS
The current study utilized VEH vs. MINO treated mice to investigate antibiotic
induced alterations in the oral microbiota and its implications on the osteoimmune
response and skeletal homeostasis within the alveolar bone complex. The commensal
microbiota has been shown to indirectly impact bone growth and modeling in health via
interactions of immune cells with osteoclasts and osteoblasts.75,76,161 While the majority
of the literature is focused on gut microbiota immunoregulatory effects impacting nonoral skeletal sites,17,75,80,161-164 fewer studies have been centered on the oral microbiota
and its immunomodulatory effects influencing alveolar bone homeostasis.76,165,166 Irie
Novince, and Darveau (2014) utilized the SPF vs. GF mouse model to discern that the
commensal oral microbiota stimulates osteoimmune mechanisms that lead to alveolar
bone loss in the healthy periodontium.76 The current investigation revealed that the
antibiotic perturbation of commensal oral microbiota critically regulates osteoimmune
response effects, which exacerbate naturally occurring bone loss in the alveolar bone
complex.
Hathaway-Schrader et al. (2019) was the first known report to demonstrate that
antibiotic perturbation of the gut microbiota impairs bone mass accrual at non-oral
skeletal sites.17 The current report is the first known study to discern that antibiotic
disruption of the oral microbiota dysregulates osteoimmune response effects and drives
bone loss in the alveolar bone complex. Oral minocycline administration to SPF C57BL/6
mice from age 6 to 12 weeks, induced sex-dependent shifts in the oral bacteriome.
Whereas minocycline treatment increased the bacterial load and altered phylum level
composition of the oral microbiota in 12-week-old male SPF mice, minocycline treatment
did not alter the bacterial load or phylum level composition of the oral microbiota in 12week-old female SPF mice. However, micro-CT study findings revealed that minocycline
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treatment exacerbated linear alveolar bone loss similarly in 12-week-old SPF male and
female SPF mice.
Supporting the minocycline treatment effects on the oral microbiota, a previous
study administered antibiotics or placebo control for one week duration and then
evaluated changes in the oral microbiota composition at the termination of treatment and
1, 2, 4, and 12 months following treatment.121 Oral administration of either ciprofloxacin
or clindamycin initially resulted in a profound microbial shift in saliva specimens
immediately after one week of treatment.121 The study reported that antibiotics induced
phyla level changes in the oral bacteriome, including Proteobacteria or candidate
division TM7.121 Proteobacteria was significantly altered by clindamycin immediately
following treatment and by ciprofloxacin immediately following treatment and 12 months
after treatment.121 Similar to the aforementioned clinical study on the effect of different
antibiotics on the oral microbiota121, we found that minocycline administration to 6 to 12week-old C57BL/6T mice resulted in a Proteobacteria-dominated oral microbiota
composition in 12-week-old male mice.
Shifts in the gut microbiota favoring the phylum Proteobacteria have been
associated with dysbiotic pro-inflammatory states,167 metabolic conditions,168 and an
imbalanced gut microbiota function.168 Recognizing that the phylum Proteobacteria has
implications for enhanced inflammatory states,167 and that inflammation of the supporting
gingival tissues can lead to alveolar bone loss,169 the increased presence of phylum
Proteobacteria is a possible mediator of the minocycline-induced alveolar bone loss in
12-week-old male mice. Along with the increase in Proteobacteria, a significant decrease
in phylum Firmicutes was seen is 12-week-old male MINO vs. VEH mice. Firmicutes are
known to contain Gram-positive bacteria and produce mostly butyrate in the human
gut.170 Studies have shown that a decrease in the Firmicutes to Bacteriodetes ratio has
71

been associated with decreased production of short chain fatty acids, which may
decrease the integrity of cellular junctions, increase mucosal permeability, and increase
inflammatory cytokines.171 Therefore, the decreased presence of Firmicutes phylum may
partially contribute to the minocycline-induced alveolar bone loss in 12-week-old male
mice.
Within the current study, 16S analysis also discerned that minocycline
administration resulted in an increased overall bacterial load in the oral microbiota of 12week-old male mice. While this may seem surprising, previous studies have indicated
that the depletion of microbiota required a combination of at least 3 antibiotics for up to 4
weeks,172,173 and single antibiotics may not be sufficient to reduce the total bacterial
load.174 Supporting the possibility that the increased bacterial load contributed to the
increase in linear alveolar bone loss found in MINO vs. VEH treated 12-week old male
mice, Abusleme et al. (2013) reported that subgingival plaque from periodontitis vs.
healthy patients demonstrated higher bacterial load and richness.175 Based on the
correlation between higher bacterial biomass and disease states, the host immune
response eliciting the destruction of periodontal tissue may be secondary to an overall
greater bacterial challenge. Considering that periodontal disease has been characterized
by an increase in bacterial load175 and abundance of specific phylum-level taxa,176 the
previous reports provide support that pathogenesis of periodontal alveolar bone loss is
secondary to both dysbiotic shifts in the oral microbiota composition and increase in
overall bacterial load.
Minocycline treatment exhibited sex-dependent effects on the oral microbiota as
no differences were seen in overall bacterial load or phylum level bacterial communities
in female mice. While there was significantly increased linear alveolar bone loss in
minocycline treated female SPF mice, the role of the oral microbiota is unclear. In a
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recently published study, Hathaway-Schrader et al. (2020) showed that specific changes
in the bacterial composition of the commensal gut microbiota alters osteoimmune
response effects at non-oral skeletal sites.164 Comparing mice colonized by segmented
filamentous bacteria (SFB) to mice not colonized by SFB revealed that the presence of a
single commensal gut bacterium has the potential to impair the accrual of bone mass in
the late growing skeleton.164 Notably, the aforementioned seminal manuscript highlights
that species level changes in microbiota communities can disrupt osteoimmune
processes which ultimately have detrimental effects on the skeleton. This research
supports the notion that species level antibiotic-induced alterations in the oral microbiota,
could contribute to the alveolar bone loss found in MINO vs. VEH mice. To determine
whether minocycline-induced shifts in the oral microbiota of female mice contributed to
the increased alveolar bone loss, further investigations evaluating more specific
taxonomy levels, such as genus and species, are indicated and necessary.
As means to elucidate whether minocycline-induced linear alveolar bone loss is
dependent on the oral microbiota, male GF C57BL/6T mice were administered MINO vs.
VEH treatment from age 6 to 12 weeks. Micro-CT analysis revealed that there were no
differences in the linear distance from CEJ to ABC in 12-week-old male MINO vs. VEH
treated GF mice. Because minocycline treatment did not influence linear alveolar bone
loss in GF mice, this supports the notion that the exacerbated linear alveolar bone loss
found in minocycline treated SPF mice was attributed antibiotic disruption of the oral
microbiota.
In order to determine whether oral minocycline administration had sustained
effects on the oral microbiota and linear alveolar bone loss, treatment was withdrawn
from sex-matched C57BL/6 SPF mice from age 12 –18 weeks. While antibiotic treatment
effects on overall bacterial load were not sustained in 18-week-old male mice following
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the withdrawal of minocycline treatment, phylum level alterations in the oral microbiota
persisted. At the 18-week time point, MINO treatment reduced the Proteobacteria
phylum to baseline and caused a significant increase in Actinobacteria and Firmicutes
phyla. Knowing that shifts in the gut microbiota favoring Firmicutes have been
associated with decreases in intestinal mucosal protection function,177 the shift towards a
Firmicutes dominated oral microbiota in 18-week-old male MINO treated mice could be
contributing to the persistent alveolar bone loss realized. The bacteria of Actinobacteria
have been shown to be involved in the modulation of mucosal permeability, the immune
system, and metabolism as an unbalanced abundance has been evidenced in several
pathological conditions, such as diphtheria, tuberculosis, and leprosy.178 Actinobacteria
have also been reported to dominate the abundance in dental supragingival plaque and
have become increasingly evident to play a role in the etiology of dental caries and
periodontal disease, which supports the notion that detrimental effects found in 18-weekold male MINO treated mice may be related to an increase in this phylum.178,179
Supporting the sustained minocycline-induced alterations in the oral microbiota of 18week-old male MINO treated mice, Zaura et al. (2015) demonstrated that exposure to
clindamycin resulted in profound changes in the genus-level oral microbial profile which
remained significant one month following cessation of antibiotic treatment.121
Minocycline treatment exhibited no significant effects on the oral bacteriome of
female mice. Paralleling findings in 12-week-old female mice, there were no differences
in overall bacterial load or phylum level composition of MINO vs. VEH treated female
mice at age 18 weeks. Because the current study showed sex-dependent minocycline
induced changes in oral microbiota composition, future investigations are necessary to
determine underlying sex-specific mechanisms, such as the role of sex hormones.
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Following the withdrawal of minocycline treatment from 12-18 weeks of age, the
linear alveolar bone loss seen in 12-week-old mice was sustained in 18-week-old male
and female mice. At the 18-week time point, male mice treated with minocycline from 6
to 12 weeks demonstrated linear alveolar bone loss at the mesiobuccal line angle and
mid-lingual aspect of the maxillary first molar. While prior research has been centered on
minocycline anti-inflammatory actions that have been linked to bone protective effects
during disease states,123,133 our research shows that minocycline administration to
healthy subjects has catabolic effects on alveolar bone. These minocycline-induced
adverse effects, which were persistent following cessation of antibiotic administration,
appear to be mediated by sustained disruption of the oral microbiota.
Findings in male mice demonstrating that minocycline treatment induced
sustained alterations in the oral microbiota and persistent detrimental effects on linear
alveolar bone loss, lead to investigating minocycline-induced alterations in osteoimmune
mechanisms regulating skeletal homeostasis within the alveolar bone complex. MicroCT studies revealed decreased cortical bone thickness in the mandibular first molar
furcation of MINO vs. VEH treated 12-week-old male SPF mice. Supporting the inferior
cortical bone phenotype found in the alveolar bone of minocycline treated 12-week-old
male SPF mice, Guss et al. (2017) found that administering broad spectrum oral
antibiotics to male C57Bl/6J mice, from 4 to 16 weeks of age, impaired cortical bone
morphological properties at non-oral skeletal sites.180
Differences in cortical bone parameters and the distance from the CEJ to ABC
may be due to alterations in osteoclastogenesis. Therefore, histological sections were
stained for tartrate resistance acid phosphatase (TRAP) to investigate osteoclast
parameters. Osteoclasts were identified as TRAP+ stained cells with 3 or more nuclei
lining the bone. Histomorphometric analysis demonstrated an increase in the size of
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osteoclasts and an increase in the perimeter of osteoclasts lining the bone surface in the
maxillary first molar furcation of MINO vs. VEH mice. Increased size and perimeter of
osteoclasts lining the bone surface, if actively resorbing bone, could result in the
decreased bone microarchitecture properties found in MINO vs. VEH treated mice.
MBM cultures were exogenously treated with minocycline to further investigate
the pro-osteoclastic effects realized in situ in the maxillary alveolar bone of MINO treated
mice. While there were no differences in number of osteoclasts, a significant increase in
osteoclast size and a trending increase in number of nuclei per osteoclast was found in
response to in vitro exogenous minocycline treatment. The increase in size and
maturation of osteoclasts in vitro parallels the increase in osteoclast size and osteoclast
perimeter per bone perimeter observed in situ, which suggests that minocycline-induced
pro-osteoclastic actions are in part independent of the oral microbiota.
To investigate mechanisms mediating the increased size of osteoclasts and
perimeter of osteoclasts per bone surface in MINO vs. VEH mice, expression of
osteoclast related genes was assessed in MBM. Prior research has discerned that the
RANKL/OPG axis critically regulates periodontitis induced alveolar bone loss, and proinflammatory signaling mediators can exacerbate periodontal bone loss.85,89,181 Dental
plaque biofilms have been reported to upregulate RANKL, downregulate OPG, and
increase the RANKL:OPG ratio.169,182,183 Although there were no differences in proosteoclastic factors (Rankl, Opg, and Dcstamp) or the RANKL:OPG ratio in the MBM of
MINO vs. VEH mice, pro-inflammatory cytokines are known to enhance RANKLmediated osteoclastogenesis.77,86 Therefore, pro-inflammatory / pro-osteoclastic cytokine
gene expression was evaluated in gingival tissue isolates from VEH vs MINO mice.
The gingival epithelium was originally considered to be a physical barrier that
protected the host from bacterial invasion, however, we now know that it plays a more
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active role in the pathogenesis of inflammatory alveolar bone loss.20 Pro-inflammatory
cytokines known to enhance RANKL-mediated osteoclastogenesis, such as Il1b, Il6,
Il17a, Tnf, Ifng, S100a8, and S100a9 were investigated. Minocycline treatment induced
no differences in pro-inflammatory mediators in the mandible gingiva. Considering that
there were no alterations in the expression of cytokines known to modulate RANKLmediated osteoclastogenesis, further research is indicated to more broadly evaluate
biologic mediators in the mandibular gingiva and bone marrow of minocycline treated
mice.
The field of osteoimmunology has shown that innate and adaptive immune cells
critically regulate osteoclastogenesis in skeletal homeostasis.77,78,148,149 Therefore, flow
cytometric analysis was performed in the MBM and CLNs of MINO vs. VEH treated mice
to evaluate changes in immune cells as candidate regulators of minocycline-induced
osteoimmune effects. A recent periodontal osteoimmunology study demonstrated that
bone damaging T-cells, specifically TH17 cells converted from FoxP3+ T cells, drive
osteolytic alveolar bone destruction secondary to periodontitis-induced changes in the
oral microbiota.67 Tsukasaki et al. (2018) concluded that bacterial invasion lead to the
proliferation of specialized TH17 cells that protect against perio-pathogenic bacteria by
promoting mucosal immune responses as well as inducing alveolar bone damage.67 Irie,
Novince, and Darveau (2014) reported that host immune response mechanisms
mediating homeostasis with the commensal oral microbiota, including increased
neutrophils, CD3+ T-lymphocytes, CD4+ T-helper cells, and IL17+ T-cells in the junctional
epithelium, induces basal inflammation supporting osteoclastogenesis and driving bone
loss in the healthy periodontium.76
Based on the prior reports by Tsukasaki et al. (2018)67 and Irie, Novince, and
Darveau (2014),76 we investigated alterations in innate immune cell populations and
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CD4+ helper T-cell subsets within the MBM environment and oral draining CNLs. Flow
cytometry outcomes demonstrating that minocycline treatment increased the frequencies
of neutrophils in the CLNs, plasmacytoid DCs in the MBM and CLNs, conventional DCs
in the MBM, TH22 cells in the CLNs, and TH1 and TH17 cells in both MBM and CLNs,
show that antibiotic perturbation of oral microbiota induced a pro-inflammatory immune
response in the MBM and oral draining lymphoid tissues. While we discerned that
minocycline altered the oral microbiota at the phylum level, antibiotic-induced proinflammatory immune cell response effects may be associated with increased mucosal
permeability, translocation of oral microbes, and overgrowth of antibiotic-resistant
opportunistic pathogens.184-191
The frequency of neutrophil cells was increased in CLNs. Important for bacterial
clearance, neutrophils have been suggested to accumulate in periodontal tissues and
precipitate in tissue destruction states.192 There is an abundance of evidence on the
phagocytic activity of neutrophils in connection with loose bacterial aggregates in the
oral cavity. However, Garant et al. (1976) concluded that “no harmful effects are suffered
as a consequence of the transmigration of neutrophils to the junctional epithelium” and
the protective wall of leukocytes reflects the host’s intention to wall off and protect itself
from bacterial invasion.193 Studies have reported that minocycline has the ability to
decrease the LPS-induced activation of macrophages194 and suppress the activation of
pro-inflammatory monocytes,195 which in part explains the reduced frequency of
inflammatory monocytes and M1-macrophages found in the MBM in response to
minocycline treatment. Considering that minocycline treatment suppressed the
frequency of inflammatory monocytes and M1-macrophages, this highlights that
minocycline administration may have altered DCs in the MBM and CLNs draining the
oral cavity.
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Two major DC subtypes are critical to periodontal immunity; plasmacytoid DCs
terminally differentiate in the bone marrow carrying the ability to produce high amounts
of type-1 INFs,196 whereas conventional DCs migrate to the oral draining lymph nodes to
present pathogen-derived peptides to T-cells.197 Plasmacytoid DCs were increased in
the marrow and CLNs, while conventional DCs were increased in the marrow of MINO
treated mice. Under inflammatory conditions, peripheral DCs reside in an immature state
and serve as sentinels that survey the periodontal tissue for invading microbes.196
Dendritic cell function has been reported to be modulated by direct interaction with
periodontal pathogens.198-200 One study demonstrated exposure to P. gingivalis in the
gingiva resulted in production of pro-inflammatory cytokines from non-immune cells in
the local tissue.198 DCs exposed to cytokines produced by gingival tissue cells induced
the generation of TH2 and TREG cells, however, DCs in direct interaction with infiltrating
bacteria induced the population of TH1 cells.199 As oral DCs are also likely to become
exposed to multiple types of bacteria simultaneously, studies have evaluated the impact
of polybacterial infection on DCs.200 While it is known that Gram-negative bacteria are
stronger inducers of inflammatory cytokines, DCs exposed to Gram-negative bacteria
selectively synergized production of Il6, Tnf, and Il12 cytokines.200 Another study
highlighted the contribution of the commensal bacteria to alveolar bone loss,
demonstrating that oral exposure of mice to P. gingivalis dramatically increases the
commensal oral bacteria load, alters the diversity of the oral microbiota, and drives
alveolar bone loss.5 In this regard, periodontal pathogen induced alterations in the oral
commensal bacteriome can stimulate maturation of DCs and production of cytokines and
chemokines with inflammatory properties.201 Several studies have demonstrated that
among the CD4+ T-cell subsets, upregulation of TH1/TH17 cells and downregulation of
TH2 cells are associated with periodontal tissue destruction.202-204 The minocycline79

induced increase in DCs paralleled the increased frequency of TH1 and TH17 cells in the
MBM and CLNs, which suggests that the upregulated DCs in the oral environment may
drive the development of pro-inflammatory TH1 / TH17 cells to exacerbate periodontal
tissue destruction.
Also under inflammatory states, oral DCs have been reported to have important
roles in antigen presenting processes to prompt the adaptive immune response.196
Moreover, DCs may migrate to the oral draining CLNs to present MHC Class II and costimulatory molecules, which enables potent activation of CD4+ T cells.196 Because we
found a decreased frequency of activated CD4+ T-cells and an increased frequency of
naïve CD4+ T-cells in the CLNs of MINO vs. VEH treated mice, this suggest that
minocycline dysregulated MHC Class II antigen processing/presentation.
Antigen presentation is an important component of innate and adaptive immune
cross talk as antigen presenting cells present self-peptides and non-self-peptides to
prompt the adaptive immune system. It has been more recently studied that bone
marrow-derived antigen presenting cells are necessary for oral T-cell education, immune
tolerance, and T-cell interactions in lymphoid tissues in periodontitis and health.63,196
Because MHC class II complexes are expressed on antigen presenting plasmacytoid
DCs, we propose a mechanism by which plasmacytoid DCs drive a pro-inflammatory
immune response secondary to minocycline perturbation of the oral microbiota.
Further demonstrating the role DCs play in activating bone-damaging CD4+ Tcells, one study has reported that in the absence of CD4+ T-cells, mice were resistant to
bacteria induced alveolar bone loss.12 Whereas the oral microbiota is essential for the
initiation and progression of periodontitis disease states in the oral cavity, tissue damage
is mediated primarily by the host immune response.61,205 When commensal oral
microbiota homeostasis is disrupted, commensals could potentially be presented by oral
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DCs to activate T-cells, thus facilitating local inflammation and bone resorption in the
alveolar bone complex.
This research demonstrates that antibiotic disruption of the oral microbiota alters
host immune response effects, which critically regulates normal osteoimmune processes
and skeletal homeostasis in the alveolar bone complex. Minocycline-induced upregulation of DCs in the marrow and lymphoid tissues draining the oral cavity highlights
that DCs are a critical modulator of oral microbiota host immune response effects driving
alveolar bone loss (Figure 19).
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Figure 19: Schematic summarizing findings in minocycline treated mice.

Due to the pharmacological profile of tetracyclines, which combines antimicrobial with anti-inflammatory and anti-apoptotic properties, oral minocycline treatment
has previously been experimentally administered in periodontal disease models. When
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administered for the treatment of periodontitis, minocycline was detected in gingival
crevicular fluid and significantly increased the proliferation of osteoblast cells, whereas
long-term exposure of these cells to tetracycline resulted in a proportional increase in
mineralized bone matrix. This suggest that minocycline has a therapeutic osteogenic
effect when administered for the treatment of periodontitis.206 These minocycline effects
are present without impacting the survival and protein expression of human gingival
fibroblasts, epithelial cells, and periodontal ligament fibroblasts.207 Taken together, these
minocycline actions in experimental periodontal disease models may explain the efficacy
of minocycline in reducing disease progression and promoting periodontal healing.208
Speaking to the clinical implications of this study, minocycline is FDA approved
as a local adjunctive therapeutic for the treatment of periodontal disease. Local
administration of minocycline microspheres, or Arestin (OraPharma, Inc., Warminster,
Pa, USA), has been shown to be advantageous when used as an adjunctive therapy to
both nonsurgical and surgical treatment in patients with moderate to severe, chronic
periodontitis.209 Compared to scaling and root planning alone, adjunctive minocycline
administration into the periodontal pocket has been shown to significantly reduce
probing depths and eliminate red-complex periodontal pathogens.209 Despite the fact
that several clinical studies have shown additional benefits when systemic antibiotics are
administered as adjuncts to periodontal treatment, clear guidelines for the use of these
agents in clinical practice are unavailable, and their slight additional benefits must be
balanced against their adverse side effects. Minocycline is also commonly prescribed to
adolescents for the treatment of dermatological conditions.210 Highlighting the clinical
relevance of this study, minocycline was administered at a human equivalent dose for
the treatment of acne. The current investigation is the first known study to delineate that
oral minocycline therapy induced disruption of the commensal oral microbiota negatively
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impacts periodontal health and homeostasis. This suggests that oral minocycline therapy
for the treatment of acne may have unintended detrimental clinical effects on the healthy
periodontium.
Future studies are needed to further advance knowledge about minocycline
effects on the oral microbiota, periodontal immune response, and alveolar bone
homeostasis. While there is an increasing prevalence of research focused on the impact
of antibiotics on the oral bacteriome, there is a lack of studies discerning effects on the
fungal component of the oral microbiota. Antibiotics are known to cause shifts in the
fungal flora within the gut, further demonstrating the need for future studies evaluating
minocycline induced changes in the oral mycobiome. Minocycline effects on non-oral
microbiota communities, such as the gut and skin flora, may contribute to the alveolar
bone loss found in response to minocycline treatment. Therefore, future studies should
investigate whether minocycline effects on the oral microbiota vs. non-oral microbiota
communities are causing alveolar bone loss. While the current osteoimmunology study
was focused on osteoclastogensis, ongoing research is needed to evaluate minocycline
effects on osteoblastogenesis in the alveolar bone complex. Considering that other
tetracycline derivatives, such as doxycycline, are commonly administered by clinicians,
future investigations could employ the reported murine antibiotic administration model to
evaluate whether other tetracycline class drugs have similar effects on alveolar bone
homeostasis and periodontal health.
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APPENDIX
Experimental Timeline

Male
C57BL/6T

Vehicle Ctrl
ABX Tx

Tx Timeline (Age):
Initiate Tx
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ABX Tx

6

12
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Figure A.1: EXPERIMENTAL TIMELINE OF
ANITBIOTIC COCKTAIL (ABX) IN VIVO. Broadspectrum antibiotic cocktail (ABX) consisted of
vancomycin (500 mg/L) targeting Gram (+) bacteria,
imipenem/cilastatin (500 mg/L) targeting Gram (+),
Gram (-), and anaerobes, and neomycin (1000 mg/L)
targeting Gram (+) and Gram (-) bacteria. ABX Tx was
supplemented in mice drinking water from 6 to 12 weeks
of age and mice were euthanized at 12 weeks.
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Figure A.2: ANTIBIOTIC COCKTAIL (ABX) EFFECTS ON
CORTICAL BONE MICROARCHITECTURE. 12-week-old
male VEH- and ABX-treated mice were euthanized, and
mandibles were harvested for micro-CT analysis. (a-f) MicroCT analysis of cortical bone thickness in mandibular first molar
furcation. (n=4-6/pg) (a-b) Representative images of cortical
bone thickness at the buccal aspect of inner cortical bone
surface (*measurement of interest defined by red
perpendicular dashed line). (a) Representative images of
cortical bone thickness at the lingual aspect of inner cortical
bone surface (*measurement of interest defined by yellow
perpendicular dashed line). (c-f) Ct.Th = cortical bone
thickness outcomes at the (c) buccal cortical plate, (d) lingual
cortical plate, and (f) combined average of the buccal / lingual
cortical plates. Unpaired t-test statistical analysis was used.
Data are reported as mean ± SEM. *p<0.05 vs. VEH. **p<0.01
vs. VEH.
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Figure A.3: ANTIBIOTIC COCKTAIL (ABX) EFFECTS ON TRABECULAR BONE
MICROARCHITECTURE. 12-week-old male VEH- and ABX-treated mice were euthanized,
and mandibles were harvested for micro-CT analysis. (a-b) Micro-CT analysis of trabecular
bone in mandibular first molar furcation. (n=4-6/pg) (a) Representative images of trabecular
bone volume fraction using cylindrical method (*region of interest defined by yellow
cylinder). (b) BV/TV = trabecular bone volume fraction. Unpaired t-test statistical analysis
was used. Data are reported as mean ± SEM. *p<0.05 vs. VEH.
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Figure A.4: ANTIBIOTIC COCKTAIL (ABX) EFFECTS ON IN SITU
OSTEOCLASTOGENESIS. 12-week-old male VEH- and ABX-treated mice were
euthanized, and maxilla harvested for histomorphometric analysis. Histomorphometric
analysis of osteoclast cellular endpoints were performed in the trabecular bone marrow
furcation of tartrate-resistant acid phosphatase (TRAP) stained maxillary first molar
sections; TRAP+ cells lining bone with ≥ 3 nuclei were designated an osteoclast. (a-b)
Representative images of furcation region of interest in TRAP-stained maxilla sections.
(c) N.OC / B.Pm = osteoclast number per bone perimeter. (d) Oc.Ar / Oc = average
osteoclast area. (e) Oc.Pm / B.Pm = osteoclast perimeter per bone perimeter. Unpaired
t-test statistical analysis was used. Data are reported as mean + SEM. *p<0.05 vs. VEH.
**p<0.01 vs. VEH.
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Figure A.5: ANTIBIOTIC COCKTAIL (ABX) EFFECTS ON INNATE IMMUNE CELLS IN
MANDIBLE BONE MARROW (MBM) AND CERVICAL LYMPH NODE (CLN). Mandible
bone marrow (MBM) and oral draining cervical lymph nodes (CLN) innate immune cell
analysis. 12-week-old male VEH- and ABX-treated mice were euthanized; MBM and CLN
cells were isolated for flow cytometric analysis (n=4-6/gp). (a-d) Neutrophil, monocyte, and
macrophage subsets are expressed relative to the CD11b+ cell population; (a)
+
lo
+
+
+
+
%CD11b Ly6C Ly6G neutrophils; (b) %CD11b Ly6G F4/80 Ly6C inflammatory
+
+
+
+
+
monocytes; (c) %CD11b MHCII CD64 M1-macrophages; (d) %CD11b MHCII M2macrophages. (e-f) Dendritic cell (DC) subsets are expressed relative to the CD11c+ cell
+
+
lo
+
+
population; (e) CD11c B220 MHCII plasmacytoid DCs; (f) CD11c CD11b B220 MHCII
conventional DCs. Unpaired t-test statistical analysis was used. Data are reported as mean
± SEM, *p<0.05 vs. VEH, **p<0.01 vs. VEH, ***p<0.001 vs. VEH.
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Figure A.6: ANTIBIOTIC COCKTAIL (ABX) EFFECTS ON TOTAL, NAÏVE, AND
ACTIVATED T-CELLS IN MANDIBLE BONE MARROW (MBM) AND CERVICAL LYMPH
NODES (CLNS). Mandible bone marrow (MBM) and oral draining cervical lymph nodes
+
+
(CLN) CD4 T-cell and CD8 T-cell flow cytometric analysis. 12-week-old male VEH- and
ABX-treated mice were euthanized; MBM and CLN cells were isolated for flow cytometric
+
+
+
analysis (n=4-6/gp). (a-c) Helper CD4 T-cell subset composition. (a) CD3 CD8 CD4 Total
+
+
+
+
CD4 Helper T-cells; (b) CD3 CD8 CD4 CD62L CD69 Naïve CD4 T-cells; (c) CD3 CD8
+
+
+
CD4 CD62L CD69 Activated CD4 T-cells. (d-f) Helper CD8 T-cell subset composition. (d)
+
+
+
+
+
+
CD3 CD4 CD8 Helper CD8 T-cells; (e) CD3 CD4 CD8 CD62L CD69 Naïve CD8 T-cells;
+
+
+
(f) CD3 CD4 CD8 CD62L CD69 Activated CD8 T-cells. Data are expressed relative to
CD3+CD4+ cells. Unpaired t-test statistical analysis was used. Data are reported as mean
± SEM, *p<0.05 vs. VEH.
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Figure A.7: ANTIBIOTIC COCKTAIL (ABX) EFFECTS ON CD4+ HELPER T-CELL
SUBSETS IN MANDIBLE BONE MARROW (MBM) AND CERVICAL LYMPH NODES
(CLNS). Mandible bone marrow (MBM) and oral draining cervical lymph nodes (CLN)
adaptive immune cell analysis. 12-week-old male VEH- and ABX-treated mice were
euthanized; MBM and CLN cells were isolated for flow cytometric analysis (n=4-6/gp).
+
+
+
+
+
(a-d) CD4 T-cell subsets composition (a) CD3 CD4 CD25 FoxP3 TREG cells; (b)
+
+
+
+
+
+
CD3 CD4 RORyt AHR+ TH22 cells (c) CD3 CD4 CD183 T-bet TH1 cells; (d)
+
+
+
+
+
CD3 CD4 RORyt AHR TH17 cells. Percentages relative to total CD3 CD4 T-cells.
Unpaired t-test statistical analysis was used. Data are reported as mean ± SEM. *p<0.05
vs. VEH. **p<0.01 vs. VEH. ***p<0.001 vs. VEH.
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Figure A.8: ANTIBIOTIC COCKTAIL (ABX) EFFECTS ON PRO-INFLAMMATORY
MEDIATORS IN MANDIBLE GINGIVA. 12-week-old male VEH and ABX treated mice
were euthanized and gingiva was isolated for qRT-PCR gene expression analysis
(n=4-6/gp). (a) Il1b mRNA (pleiotropic inflammatory cytokine); (b) Il6 mRNA
(pleiotropic inflammatory cytokine); (c) Il17 mRNA (TH17 cytokine); (d) Tnf mRNA
(pleiotropic inflammatory cytokine); (e) Ifng mRNA (TH1 cytokine). Relative
-ΔΔCT
quantification of mRNA was performed via the comparative CT method ( 2
); Rn18s
was utilized as an internal control gene. Data are reported as mean ± SEM. *p<0.05
vs. VEH.
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